<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front><journal-meta><journal-id journal-id-type="nlm-ta">Infect Drug Resist</journal-id><journal-id journal-id-type="iso-abbrev">Infect Drug Resist</journal-id><journal-id journal-id-type="publisher-id">idr</journal-id><journal-title-group><journal-title>Infection and Drug Resistance</journal-title></journal-title-group><issn pub-type="epub">1178-6973</issn><publisher><publisher-name>Dove</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">38711471</article-id><article-id pub-id-type="pmc">11073536</article-id><article-id pub-id-type="publisher-id">455146</article-id><article-id pub-id-type="doi">10.2147/IDR.S455146</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Clinical and Molecular Characteristics of Patients with Bloodstream Infections Caused by KPC and NDM Co-Producing Carbapenem-Resistant <italic toggle="yes">Klebsiella pneumoniae</italic></article-title><alt-title alt-title-type="running-authors">Li et al</alt-title><alt-title alt-title-type="running-title">Li et al</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Li</surname><given-names>Jiayang</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="ft0001" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Wu</surname><given-names>Wenqi</given-names></name><xref rid="aff0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="ft0001" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Meilin</given-names></name><xref rid="aff0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Zhitao</given-names></name><xref rid="aff0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Jiajie</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Qiu</surname><given-names>Mingjie</given-names></name><xref rid="aff0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Li</given-names></name><xref rid="aff0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4697-4762</contrib-id><name><surname>Ren</surname><given-names>Jianan</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Xiuwen</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="an0001" ref-type="corresp"/></contrib><aff id="aff0001"><label>1</label><institution>School of Medicine, Southeast University</institution>, <addr-line>Nanjing</addr-line>, <country>People&#x2019;s Republic of China</country></aff><aff id="aff0002"><label>2</label><institution>Research Institute of General Surgery, Jinling Hospital, School of Medicine, Southeast University</institution>, <addr-line>Nanjing</addr-line>, <country>People&#x2019;s Republic of China</country></aff><aff id="aff0003"><label>3</label><institution>School of Medicine, Nanjing University</institution>, <addr-line>Nanjing</addr-line>, <country>People&#x2019;s Republic of China</country></aff><aff id="aff0004"><label>4</label><institution>Nanjing Medical University</institution>, <addr-line>Nanjing</addr-line>, <country>People&#x2019;s Republic of China</country></aff></contrib-group><author-notes><corresp id="an0001">Correspondence: Xiuwen Wu; Jianan Ren, Research Institute of General Surgery, Jinling Hospital, School of Medicine, Southeast University, <addr-line>305 East Zhongshan Road</addr-line>, <addr-line>Nanjing</addr-line>, <addr-line>210002</addr-line>, <country>People&#x2019;s Republic of China</country>, Email wuxiuwen@nju.edu.cn; jiananr@nju.edu.cn</corresp><fn id="ft0001"><label>*</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date pub-type="epub"><day>02</day><month>5</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>17</volume><fpage>1685</fpage><lpage>1697</lpage><history><date date-type="received"><day>15</day><month>12</month><year>2023</year></date><date date-type="accepted"><day>22</day><month>4</month><year>2024</year></date></history><permissions><copyright-statement>&#xA9; 2024 Li et al.</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Li et al.</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/3.0/</ali:license_ref><license-p>This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution &#x2013; Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link>).</license-p></license></permissions><abstract><sec id="s2001"><title>Purpose</title><p><italic toggle="yes">Klebsiella pneumoniae</italic> carbapenemase (KPC) and New Delhi metallo-&#x3B2;-lactamase (NDM) co-producing carbapenem-resistant <italic toggle="yes">Klebsiella pneumoniae</italic> (KPC-NDM-CRKP) isolates have been increasingly reported worldwide but have not yet been systematically studied. Thus, we have conducted a study to compare the risk factors, molecular characteristics, and mortality involved in clinical bloodstream infections (BSIs) caused by KPC-NDM-CRKP and KPC-CRKP strains.</p></sec><sec id="s2002"><title>Methods</title><p>A retrospective study was conducted on 231 patients with BSIs caused by CRKP at Jinling Hospital in China from January 2020 to December 2022. Antimicrobial susceptibility testing, carbapenemase genes detection and whole-genome sequencing were performed subsequently.</p></sec><sec id="s2003"><title>Results</title><p>Overall, 231 patients were included in this study: 25 patients with KPC-NDM-CRKP BSIs and 206 patients with KPC-CRKP BSIs. Multivariate analysis implicated ICU-acquired BSI, surgery within 30 days, and longer stay of hospitalization prior to CRKP isolation as independent risk factors for KPC-NDM-CRKP BSIs. The 30-day mortality rate of the KPC-NDM-CRKP BSIs group was 56% (14/25) compared with 32.5% (67/206) in the KPC-CRKP BSIs control group (<italic toggle="yes">P</italic> = 0.02). The ICU-acquired BSIs, APACHE II score at BSI onset, and BSIs caused by KPC-NDM-CRKP were independent predictors for 30-day mortality in patients with CRKP bacteremia. The most prevalent ST in KPC-NDM-CRKP isolates was ST11 (23/25, 92%), followed by ST15 (2/25, 8%).</p></sec><sec id="s2004"><title>Conclusion</title><p>In patients with CRKP BSIs, KPC-NDM-CRKP was associated with an excess of mortality. The likelihood that KPC-NDM-CRKP will become the next &#x201C;superbug&#x201D; highlights the significance of epidemiologic surveillance and clinical awareness of this pathogen.</p></sec></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>KPC and NDM co-producing carbapenem-resistant <italic toggle="yes">Klebsiella pneumoniae</italic></kwd><kwd>Bloodstream infections</kwd><kwd>risk factors</kwd><kwd>molecular characteristics</kwd><kwd>mortality</kwd></kwd-group><funding-group><funding-statement>This work was supported by the National Natural Science Foundation of China (grant number 82272237), Jiangsu Provincial Medical Innovation Center (grant number CXZX202217), and Key Research and Development Program of Jiangsu Province (grant number BE2022823).</funding-statement></funding-group><counts><fig-count count="0"/><table-count count="15"/><ref-count count="45"/><page-count count="13"/></counts></article-meta></front>
  <body>
    <sec sec-type="intro" id="s0001">
      <title>Introduction</title>
      <p>Carbapenem-resistant <italic toggle="yes">Klebsiella pneumoniae</italic> (CRKP) represents a catastrophic threat to global public health and clinical settings due to the presence of mobile carbapenemases. <italic toggle="yes">Klebsiella pneumoniae</italic> carbapenemase (KPC, class A) and New Delhi metallo-&#x3B2;-lactamase (NDM, class B) are two of the more prevalently encountered carbapenemases worldwide.<xref rid="cit0001" ref-type="bibr">1</xref>,<xref rid="cit0002" ref-type="bibr">2</xref> Recently, KPC and NDM co-producing <italic toggle="yes">K. pneumoniae</italic> (KPC-NDM-CRKP) isolates have been increasingly reported in China and many regions of the world.<xref rid="cit0003" ref-type="bibr">3</xref>,<xref rid="cit0004" ref-type="bibr">4</xref></p>
      <p>KPC and NDM belong to different carbapenemase classes. The infection caused by KPC-producing organisms has been partially solved by the introduction of newer &#x3B2;-lactamase inhibitors, such as avibactam, relebactam, and vaborbactam. This solution is limited because these newer &#x3B2;-lactamase inhibitors could not cover NDM. In addition, NDM is able to hydrolyze all &#x3B2;-lactams except monobactams, while KPC can also deactivate monobactams.<xref rid="cit0005" ref-type="bibr">5&#x2013;7</xref> Thus, the emergence of KPC-NDM-CRKPs results in higher level of antimicrobial resistance and extremely limited treatment options, which may further lead to increased mortality rates.<xref rid="cit0003" ref-type="bibr">3</xref>,<xref rid="cit0008" ref-type="bibr">8</xref></p>
      <p>However, several studies have been conducted on risk factors and clinical outcomes for CRKP bloodstream infections (BSIs).<xref rid="cit0009" ref-type="bibr">9</xref> The results of risk factors are highly heterogeneous, and deaths attributable to CRKP BSIs vary from 20% to 45%.<xref rid="cit0010" ref-type="bibr">10</xref>,<xref rid="cit0011" ref-type="bibr">11</xref> To the best of our knowledge, no studies have focused on BSIs caused by KPC-NDM-CRKPs. The identification of risk factors and mortality of infections caused by KPC-NDM-CRKPs is important to highlight the significance of epidemiologic surveillance and clinical awareness of this pathogen. Thus, we have conducted a study to compare the risk factors, molecular characteristics, and mortality involved in clinical BSIs caused by KPC-NDM-CRKP and KPC-CRKP strains.</p>
    </sec>
    <sec id="s0002">
      <title>Materials and Methods</title>
      <sec id="s0002-s2001">
        <title>Study Design</title>
        <p>The study was conducted at Jinling Hospital, a teaching hospital in Nanjing, mainland China, with a 2500-bed capacity. Clinically isolated CRKPs of BSIs were continuously collected over three years, from January 1, 2020, to December 31, 2022. Only the first bacteremia episode for each patient was included in this retrospective study.</p>
      </sec>
      <sec id="s0002-s2002">
        <title>Study Population and Data Collection</title>
        <p>All hospitalized patients (aged &#x2265; 16 years) with BSIs caused by CRKP were included in this study. Data were collected from the medical records, including gender and age, underlying diseases (solid cancer, hypertension, cardiovascular disease, gastrointestinal fistula, diabetes mellitus, chronic liver disease, fatty liver, biliary tract disease, chronic renal failure, neurologic disorder, trauma, and malnutrition), surgery performed in the past 30 days prior to CRKP isolation, probable source of BSI, empirical antibiotic treatment, days of hospitalization prior to CRKP isolation, total length of hospital stay, and ICU stay. BSI episodes were classified as community- or ICU-acquired, as previously described.<xref rid="cit0011" ref-type="bibr">11</xref> Appropriate empirical treatment was defined as the use of at least one active antimicrobial agent within 72 hours of BSI onset, and the dose was up to current medical standards.</p>
        <p>Laboratory data including white blood cell (WBC) count, neutrophilic granulocyte percentage (NEUT%), C-reactive protein (CRP), procalcitonin (PCT), platelet count, and albumin were also obtained at the time of the first positive BSI episode. In addition, the severity of illness at the onset of BSI was estimated by the Pitt bacteremia score and the Acute Physiology and Chronic Health Evaluation II (APACHE II) score. The presence of sepsis or septic shock was also assessed by Sepsis 3.0 when bacteremia occurred.<xref rid="cit0012" ref-type="bibr">12</xref> The outcome was measured as 30-day mortality, which was defined as the death occurring within 30 days after the onset of CRKP BSI.</p>
      </sec>
      <sec id="s0002-s2003">
        <title>Microbiological Methods</title>
        <p>CRKP was defined as <italic toggle="yes">K. pneumoniae</italic> harboring the carbapenemase genes or having a minimum inhibitory concentration (MIC) of &#x2265; 2 mg/L for ertapenem, &#x2265; 4 mg/L for imipenem or meropenem, according to Clinical and Laboratory Standards Institute guidelines (CLSI-M100, 2020). Confirmation of the <italic toggle="yes">K. pneumoniae</italic> isolates and antimicrobial susceptibility testing were performed using the Vitek 2 system (bioMe&#xB4;rieux, Marcy l&#x2019;Etoile, France). Polymerase chain reaction (PCR) and NG-test Carba 5 (NG Biotech, Guipry, France) were used to determine the presence of carbapenemase genes, including <italic toggle="yes">bla</italic><sub>KPC</sub>, <italic toggle="yes">bla</italic><sub>NDM</sub>, <italic toggle="yes">bla</italic><sub>IMP</sub>, <italic toggle="yes">bla</italic><sub>VIM</sub>, and <italic toggle="yes">bla</italic><sub>OXA-48-like</sub>.<xref rid="cit0013" ref-type="bibr">13</xref>,<xref rid="cit0014" ref-type="bibr">14</xref> The PCR primers were based on previous references.<xref rid="cit0009" ref-type="bibr">9</xref></p>
        <p>The following antimicrobial agents were tested: piperacillin-tazobactam, cefoperazone-sulbactam, ceftazidime, cefepime, aztreonam, ertapenem, imipenem, meropenem, amikacin, tobramycin, ciprofloxacin, levofloxacin, doxycycline, minocycline, tigecycline, colistin, and trimethoprim-sulfamethoxazole. The interpretive criteria for tigecycline and colistin were based on the Food and Drug Administration (FDA) and European Committee on Antimicrobial Susceptibility Testing (EUCAST, version 13.0) breakpoints, respectively. The other antimicrobial agents MICs were interpreted according to CLSI breakpoints (M100, 2020). <italic toggle="yes">Pseudomonas aeruginosa</italic> ATCC 27853 and <italic toggle="yes">Escherichia coli</italic> ATCC 25922 were used as quality controls.</p>
        <p>Genomic DNA extraction of 242 CRKP isolates was performed with the TIANamp Bacteria DNA Kit (Tiangen Biotech) and subjected to whole-genome sequencing (WGS) on the Illumina NovaSeq PE150 platform. Assemblies were performed using SPAdes (version 3.13.0). Kleborate (version 2.3.0),<xref rid="cit0015" ref-type="bibr">15</xref> ResFinder,<xref rid="cit0016" ref-type="bibr">16</xref> and CARD<xref rid="cit0017" ref-type="bibr">17</xref> were used to determine multilocus sequence typing (MLST), resistance and virulence determinants. All sequence data have been submitted to the National Center for Biotechnology Information (NCBI) database under BioProject PRJNA1092646.</p>
      </sec>
      <sec id="s0002-s2004">
        <title>Statistical Analysis</title>
        <p>Data were expressed as the medians with interquartile range (IQR), the means &#xB1; standard deviation (SD), or n (%) as appropriate. Categorical variables were analyzed by the &#x3C7;<sup>2</sup> test or Fisher&#x2019;s exact test and continuous variables were compared using the Student&#x2019;s <italic toggle="yes">t</italic> test or the Mann&#x2013;Whitney <italic toggle="yes">U</italic>-test, as appropriate. Logistic regression was used to identify risk factors for KPC-NDM-CRKP BSIs and independent predictors of 30-day mortality. All variables with <italic toggle="yes">P</italic> &lt; 0.1, age, and sex were included in the multivariate model in a forward stepwise with the use of the likelihood-ratio test. All statistical analyses were performed by SPSS software (Version 25.0). A two-sided <italic toggle="yes">P</italic>-value &lt; 0.05 was considered statistically significant.</p>
      </sec>
    </sec>
    <sec id="s0003">
      <title>Results</title>
      <sec id="s0003-s2001">
        <title>Clinical Characteristics of Patients with CRKP BSIs</title>
        <p>A total of 242 consecutive cases of CRKP BSIs were collected over three years, between January 1, 2020, and December 31, 2022. Overall, 231 patients were included in this study: 25 patients with KPC-NDM-CRKP BSIs and 206 patients with KPC-CRKP BSIs. One isolate coharboring <italic toggle="yes">bla</italic><sub>KPC-2</sub> and <italic toggle="yes">bla</italic><sub>OXA-232</sub>, as well as three isolates carrying <italic toggle="yes">bla</italic><sub>NDM-1</sub>, one isolate carrying <italic toggle="yes">bla</italic><sub>NDM-5</sub>, and six isolates carrying <italic toggle="yes">bla</italic><sub>OXA-232</sub> were excluded due to the small sample size (<underline><ext-link xlink:href="https://www.dovepress.com/get_supplementary_file.php?f=455146.pdf" ext-link-type="uri">Supplementary Figure 1</ext-link></underline>).</p>
        <p>The number of CRKP isolates included in this study was 84 in 2020, 68 in 2021, and 79 in 2022. The proportion of KPC-NDM-CRKP isolates was 11.9% (10/84) in 2020, 13.2% (9/68) in 2021, and 7.6% (6/79) in 2022 (<underline><ext-link xlink:href="https://www.dovepress.com/get_supplementary_file.php?f=455146.pdf" ext-link-type="uri">Supplementary Figure 2</ext-link></underline>). The mean age was 52.3 &#xB1; 15.3 years old, with a male predominance (n = 177, 76.6%), and 140 cases (60.6%) were ICU-acquired BSIs. The most common underlying diseases were gastrointestinal fistula (n = 91, 39.4%), biliary tract disease (n = 79, 34.2%), hypertension (n = 76, 32.9%), and diabetes mellitus (n = 51, 22.1%). Ninety-two (39.8%) patients underwent surgery in the past 30 days prior to CRKP isolation.</p>
        <p>The main sources of CRKP BSIs were abdomen (n = 177, 76.6%) and respiratory tract (n = 40, 17.3%). A total of 121 patients (52.4%) developed sepsis or septic shock at BSI onset. The three major antimicrobial agents of empirical treatment were carbapenem-containing regimens (n = 177, 76.6%), tigecycline-containing regimens (n = 75, 32.5%), and colistin-containing regimens (n = 56, 24.2%). The length of hospital stay was 41 (25&#x2013;67) days and the duration of ICU stay was 30 (13&#x2013;51) days.</p>
      </sec>
      <sec id="s0003-s2002">
        <title>Risk Factors Associated with KPC-NDM-CRKP BSIs</title>
        <p>The clinical characteristics of KPC-NDM-CRKP and KPC-CRKP bacteremia are shown in <xref rid="t0001" ref-type="table">Table 1</xref>. The mean age was comparable between patients with KPC-NDM-CRKP and KPC-CRKP BSIs. A male preponderance was observed in both groups. Neither sex nor age were associated with KPC-NDM-CRKP BSIs. ICU-acquired BSIs were identified in more KPC-NDM-CRKP patients (21/25, 84%) than in KPC-CRKP patients (119/206, 57.8%) (<italic toggle="yes">P</italic> = 0.011). Comparing KPC-NDM-CRKP BSIs to KPC-CRKP BSIs, the percentage of patients with hypertension or surgery within 30 days or longer hospitalization before CRKP isolation was higher, although the difference was not statistically significant (0.05 &lt; <italic toggle="yes">P</italic> &lt; 0.1).<table-wrap position="float" id="t0001"><label>Table 1</label><caption><p>Clinical Characteristics and Infection Data of Patients with BSIs Caused by KPC-NDM-CRKP and KPC-CRKP</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Characteristics</th><th rowspan="1" colspan="1">KPC-NDM-CRKP BSI (n=25)</th><th rowspan="1" colspan="1">KPC-CRKP BSI (n=206)</th><th rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age, years, mean &#xB1; SD</td><td rowspan="1" colspan="1">54.2 &#xB1; 12.3</td><td rowspan="1" colspan="1">52.1 &#xB1; 15.7</td><td rowspan="1" colspan="1">0.546</td></tr><tr><td rowspan="1" colspan="1">Male sex</td><td rowspan="1" colspan="1">21 (84%)</td><td rowspan="1" colspan="1">156 (75.7%)</td><td rowspan="1" colspan="1">0.356</td></tr><tr><td rowspan="1" colspan="1"><bold>Acquisition</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x2003;Community-acquired</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">6 (2.9%)</td><td rowspan="1" colspan="1">1.000</td></tr><tr><td rowspan="1" colspan="1">&#x2003;ICU-acquired</td><td rowspan="1" colspan="1">21 (84%)</td><td rowspan="1" colspan="1">119 (57.8%)</td><td rowspan="1" colspan="1">0.011*</td></tr><tr><td rowspan="1" colspan="1"><bold>Underlying conditions</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x2003;Solid cancer</td><td rowspan="1" colspan="1">3 (12%)</td><td rowspan="1" colspan="1">27 (13.1%)</td><td rowspan="1" colspan="1">1.000</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Hypertension</td><td rowspan="1" colspan="1">12 (48%)</td><td rowspan="1" colspan="1">64 (31.1%)</td><td rowspan="1" colspan="1">0.089</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Cardiovascular disease</td><td rowspan="1" colspan="1">4 (16%)</td><td rowspan="1" colspan="1">30 (14.6%)</td><td rowspan="1" colspan="1">1.000</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Neurologic disorder</td><td rowspan="1" colspan="1">1 (4%)</td><td rowspan="1" colspan="1">38 (18.4%)</td><td rowspan="1" colspan="1">0.124</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Diabetes mellitus</td><td rowspan="1" colspan="1">3 (12%)</td><td rowspan="1" colspan="1">48 (23.3%)</td><td rowspan="1" colspan="1">0.198</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Gastrointestinal fistula</td><td rowspan="1" colspan="1">12 (48%)</td><td rowspan="1" colspan="1">79 (38.3%)</td><td rowspan="1" colspan="1">0.351</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Chronic renal failure</td><td rowspan="1" colspan="1">1 (4%)</td><td rowspan="1" colspan="1">14 (6.8%)</td><td rowspan="1" colspan="1">0.916</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Fatty liver</td><td rowspan="1" colspan="1">2 (8%)</td><td rowspan="1" colspan="1">24 (11.7%)</td><td rowspan="1" colspan="1">0.833</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Chronic liver disease</td><td rowspan="1" colspan="1">3 (12%)</td><td rowspan="1" colspan="1">19 (9.2%)</td><td rowspan="1" colspan="1">0.932</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Biliary tract disease</td><td rowspan="1" colspan="1">8 (32%)</td><td rowspan="1" colspan="1">71 (34.5%)</td><td rowspan="1" colspan="1">0.806</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Malnutrition</td><td rowspan="1" colspan="1">2 (8%)</td><td rowspan="1" colspan="1">27 (13.1%)</td><td rowspan="1" colspan="1">0.683</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Trauma</td><td rowspan="1" colspan="1">6 (24%)</td><td rowspan="1" colspan="1">28 (13.6%)</td><td rowspan="1" colspan="1">0.277</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Surgery within 30 days</td><td rowspan="1" colspan="1">14 (56%)</td><td rowspan="1" colspan="1">78 (37.9%)</td><td rowspan="1" colspan="1">0.080</td></tr><tr><td rowspan="1" colspan="1"><bold>Source of BSI</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x2003;Respiratory tract</td><td rowspan="1" colspan="1">1 (4%)</td><td rowspan="1" colspan="1">39 (18.9%)</td><td rowspan="1" colspan="1">0.113</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Abdomen</td><td rowspan="1" colspan="1">22 (88%)</td><td rowspan="1" colspan="1">155 (75.2%)</td><td rowspan="1" colspan="1">0.155</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Urinary tract</td><td rowspan="1" colspan="1">1 (4%)</td><td rowspan="1" colspan="1">9 (4.4%)</td><td rowspan="1" colspan="1">1.000</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Skin and soft tissue</td><td rowspan="1" colspan="1">1 (4%)</td><td rowspan="1" colspan="1">3 (1.5%)</td><td rowspan="1" colspan="1">0.370</td></tr><tr><td rowspan="1" colspan="1"><bold>Infection data</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x2003;WBC count, &#xD7;10<sup>9</sup>/L, median (IQR)</td><td rowspan="1" colspan="1">9.2 (4.8&#x2013;18.5)</td><td rowspan="1" colspan="1">10.1 (6.5&#x2013;15.1)</td><td rowspan="1" colspan="1">0.796</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Albumin, g/L, mean &#xB1; SD</td><td rowspan="1" colspan="1">31.1 &#xB1; 4.7</td><td rowspan="1" colspan="1">31.4 &#xB1; 5.0</td><td rowspan="1" colspan="1">0.794</td></tr><tr><td rowspan="1" colspan="1">&#x2003;PCT, &#x3BC;g/L, median (IQR)</td><td rowspan="1" colspan="1">11.8 (1.8&#x2013;28.5)</td><td rowspan="1" colspan="1">3.6 (1&#x2013;13.5)</td><td rowspan="1" colspan="1">0.117</td></tr><tr><td rowspan="1" colspan="1">&#x2003;CRP, mg/L, median (IQR)</td><td rowspan="1" colspan="1">147.6 (74.9&#x2013;204.6)</td><td rowspan="1" colspan="1">143.2 (90.2&#x2013;204)</td><td rowspan="1" colspan="1">0.872</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Platelet count, &#xD7;10<sup>9</sup>/L, median (IQR)</td><td rowspan="1" colspan="1">133 (47&#x2013;238.5)</td><td rowspan="1" colspan="1">171 (90.2&#x2013;251.2)</td><td rowspan="1" colspan="1">0.619</td></tr><tr><td rowspan="1" colspan="1">&#x2003;NEUT%, median (IQR)</td><td rowspan="1" colspan="1">90.4 (77.6&#x2013;93.6)</td><td rowspan="1" colspan="1">88.8 (83.5&#x2013;93)</td><td rowspan="1" colspan="1">0.877</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Hospital stay prior to CRKP isolation, median (IQR)</td><td rowspan="1" colspan="1">20 (8&#x2013;32.5)</td><td rowspan="1" colspan="1">15 (5&#x2013;25)</td><td rowspan="1" colspan="1">0.099</td></tr><tr><td rowspan="1" colspan="1">&#x2003;ICU stay, median (IQR)</td><td rowspan="1" colspan="1">32 (18.5&#x2013;67.5)</td><td rowspan="1" colspan="1">29 (11&#x2013;51)</td><td rowspan="1" colspan="1">0.162</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Full hospital stay, median (IQR)</td><td rowspan="1" colspan="1">42 (19.5&#x2013;89)</td><td rowspan="1" colspan="1">40.5 (25&#x2013;66)</td><td rowspan="1" colspan="1">0.761</td></tr><tr><td rowspan="1" colspan="1">&#x2003;APACHE II score at infection onset, median (IQR)</td><td rowspan="1" colspan="1">17 (8.5&#x2013;21)</td><td rowspan="1" colspan="1">11 (7&#x2013;18)</td><td rowspan="1" colspan="1">0.192</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Pitt bacteremia score at infection onset, median (IQR)</td><td rowspan="1" colspan="1">4 (2&#x2013;5)</td><td rowspan="1" colspan="1">2 (0&#x2013;4)</td><td rowspan="1" colspan="1">0.023*</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Sepsis/septic shock at infection onset</td><td rowspan="1" colspan="1">16 (64%)</td><td rowspan="1" colspan="1">105 (51%)</td><td rowspan="1" colspan="1">0.218</td></tr><tr><td rowspan="1" colspan="1"><bold>Empirical therapy</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x2003;Monotherapy</td><td rowspan="1" colspan="1">5 (20%)</td><td rowspan="1" colspan="1">69 (33.5%)</td><td rowspan="1" colspan="1">0.172</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Combination therapy</td><td rowspan="1" colspan="1">20 (80%)</td><td rowspan="1" colspan="1">137 (66.5%)</td><td rowspan="1" colspan="1">0.172</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Fluoroquinolone-containing regimens</td><td rowspan="1" colspan="1">4 (16%)</td><td rowspan="1" colspan="1">27 (13.1%)</td><td rowspan="1" colspan="1">0.928</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Aminoglycoside-containing regimens</td><td rowspan="1" colspan="1">3 (12%)</td><td rowspan="1" colspan="1">12 (5.8%)</td><td rowspan="1" colspan="1">0.451</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Cephalosporin-containing regimens</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">11 (5.3%)</td><td rowspan="1" colspan="1">0.492</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Carbapenem-containing regimens</td><td rowspan="1" colspan="1">16 (64%)</td><td rowspan="1" colspan="1">161 (78.2%)</td><td rowspan="1" colspan="1">0.114</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Tigecycline-containing regimens</td><td rowspan="1" colspan="1">9 (36%)</td><td rowspan="1" colspan="1">66 (32%)</td><td rowspan="1" colspan="1">0.690</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Colistin-containing regimens</td><td rowspan="1" colspan="1">6 (24%)</td><td rowspan="1" colspan="1">50 (24.3%)</td><td rowspan="1" colspan="1">0.976</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Ceftazidime-avibactam-containing regimens</td><td rowspan="1" colspan="1">6 (24%)</td><td rowspan="1" colspan="1">20 (9.7%)</td><td rowspan="1" colspan="1">0.072</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Inappropriate empirical treatment</td><td rowspan="1" colspan="1">14 (56%)</td><td rowspan="1" colspan="1">120 (58.3%)</td><td rowspan="1" colspan="1">0.829</td></tr><tr><td rowspan="1" colspan="1"><bold>30-day mortality</bold></td><td rowspan="1" colspan="1">14 (56%)</td><td rowspan="1" colspan="1">67 (32.5%)</td><td rowspan="1" colspan="1">0.020*</td></tr></tbody></table><table-wrap-foot><fn id="tfn0001"><p><bold>Notes</bold>: Data are presented as No. (%) of patients unless otherwise specified. *<italic toggle="yes">P</italic> &lt; 0.05, the comparison between KPC-NDM-CRKP BSI and KPC-CRKP BSI.</p></fn><fn id="tfn0002"><p><bold>Abbreviations</bold>: KPC, <italic toggle="yes">Klebsiella pneumoniae</italic> carbapenemase; NDM, New Delhi metallo-&#x3B2;-lactamase; CRKP, carbapenem-resistant <italic toggle="yes">Klebsiella pneumoniae</italic>; KPC-NDM-CRKP, KPC and NDM co-producing carbapenem-resistant <italic toggle="yes">Klebsiella pneumoniae</italic>; KPC-CRKP, KPC-producing carbapenem-resistant <italic toggle="yes">Klebsiella pneumoniae</italic>; BSI, bloodstream infection; ICU, intensive care unit; WBC, white blood cell; PCT, procalcitonin; CRP, C-reactive protein; NEUT%, neutrophilic granulocyte percentage; APACHE, acute physiologic and chronic health evaluation; SD, standard deviation; IQR, interquartile range.</p></fn></table-wrap-foot></table-wrap>
</p>
        <p>When entering the multivariate regression analysis, ICU-acquired BSIs (95% CI 1.216&#x2013;11.631; <italic toggle="yes">P</italic> = 0.021), surgery within 30 days (95% CI 1.055&#x2013;6.203; <italic toggle="yes">P</italic> = 0.038), and longer stay of hospitalization prior to CRKP isolation (95% CI 1.003&#x2013;1.047; <italic toggle="yes">P</italic> = 0.023) were more likely to get KPC-NDM-CRKP BSIs (<xref rid="t0002" ref-type="table">Table 2</xref>).<table-wrap position="float" id="t0002"><label>Table 2</label><caption><p>Multivariable Logistic Regression of Risk Factors Independently Associated with KPC-NDM-CRKP BSIs</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1">Variables</th><th colspan="2" rowspan="1">Univariate Analysis</th><th colspan="2" rowspan="1">Multivariate Analysis</th></tr><tr><th rowspan="1" colspan="1">OR (95% CI)</th><th rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th><th rowspan="1" colspan="1">OR (95% CI)</th><th rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age</td><td rowspan="1" colspan="1">1.009 (0.982&#x2013;1.037)</td><td rowspan="1" colspan="1">0.501</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">1.683 (0.551&#x2013;5.135)</td><td rowspan="1" colspan="1">0.361</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">ICU-acquired</td><td rowspan="1" colspan="1">3.838 (1.272&#x2013;11.582)</td><td rowspan="1" colspan="1">0.017*</td><td rowspan="1" colspan="1">3.761 (1.216&#x2013;11.631)</td><td rowspan="1" colspan="1">0.021*</td></tr><tr><td rowspan="1" colspan="1">Hypertension</td><td rowspan="1" colspan="1">2.048 (0.886&#x2013;4.736)</td><td rowspan="1" colspan="1">0.094</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Surgery within 30 days</td><td rowspan="1" colspan="1">2.089 (0.903&#x2013;4.830)</td><td rowspan="1" colspan="1">0.085</td><td rowspan="1" colspan="1">2.558 (1.055&#x2013;6.203)</td><td rowspan="1" colspan="1">0.038*</td></tr><tr><td rowspan="1" colspan="1">Hospital stay prior to CRKP isolation</td><td rowspan="1" colspan="1">1.023 (1.003&#x2013;1.043)</td><td rowspan="1" colspan="1">0.023*</td><td rowspan="1" colspan="1">1.025 (1.003&#x2013;1.047)</td><td rowspan="1" colspan="1">0.023*</td></tr></tbody></table><table-wrap-foot><fn id="tfn0003"><p><bold>Notes</bold>: *<italic toggle="yes">P</italic> &lt; 0.05.</p></fn><fn id="tfn0004"><p><bold>Abbreviations</bold>: KPC, <italic toggle="yes">Klebsiella pneumoniae</italic> carbapenemase; NDM, New Delhi metallo-&#x3B2;-lactamase; CRKP, carbapenem-resistant <italic toggle="yes">Klebsiella pneumoniae</italic>; KPC-NDM-CRKP, KPC and NDM co-producing carbapenem-resistant <italic toggle="yes">Klebsiella pneumoniae</italic>; BSI, bloodstream infection; ICU, intensive care unit; OR, odds ratio; CI, confidence interval.</p></fn></table-wrap-foot></table-wrap>
</p>
      </sec>
      <sec id="s0003-s2003">
        <title>Percentage of Antimicrobial Resistance of KPC-NDM-CRKP and KPC-CRKP Strains</title>
        <p>Overall, both KPC-NDM-CRKP and KPC-CRKP strains exhibited high antimicrobial-resistant rates for piperacillin-tazobactam (231/231, 100%), cefoperazone-sulbactam (229/231, 99.1%), ceftazidime (230/231, 99.6%), cefepime (229/231, 99.1%), aztreonam (231/231, 100%), ertapenem (231/231, 100%), imipenem (231/231, 100%), meropenem (231/231, 100%), tobramycin (191/231, 82.7%), ciprofloxacin (230/231, 99.6%), and levofloxacin (229/231, 99.1%). For KPC-NDM-CRKPs, 32% (8/25) were resistant to tigecycline, and 12% (3/25) were resistant to colistin. For KPC-CRKPs, 35.4% (73/206) were resistant to tigecycline, and 9.7% (20/206) were resistant to colistin. It is noteworthy that KPC-NDM-CRKP isolates had significantly higher resistance rates to amikacin and trimethoprim-sulfamethoxazole than those of KPC-CRKP isolates (<italic toggle="yes">P</italic> = 0.004 and &lt; 0.001, respectively). Nevertheless, the antimicrobial resistance rate to doxycycline of KPC-CRKP isolates was significantly higher than that of KPC-NDM-CRKP isolates (168/206, 81.6% vs 11/25, 44%, <italic toggle="yes">P</italic> &lt; 0.001) (<xref rid="t0003" ref-type="table">Table 3</xref>).<table-wrap position="float" id="t0003"><label>Table 3</label><caption><p>Percentage of Antimicrobial Resistance of CRKP Strains</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Antimicrobial agents</th><th rowspan="1" colspan="1">KPC-NDM-CRKP (n=25)</th><th rowspan="1" colspan="1">KPC-CRKP (n=206)</th><th rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Piperacillin-tazobactam</td><td rowspan="1" colspan="1">25 (100%)</td><td rowspan="1" colspan="1">206 (100%)</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Cefoperazone-sulbactam</td><td rowspan="1" colspan="1">25 (100%)</td><td rowspan="1" colspan="1">204 (99%)</td><td rowspan="1" colspan="1">1.000</td></tr><tr><td rowspan="1" colspan="1">Ceftazidime</td><td rowspan="1" colspan="1">25 (100%)</td><td rowspan="1" colspan="1">205 (99.5%)</td><td rowspan="1" colspan="1">1.000</td></tr><tr><td rowspan="1" colspan="1">Cefepime</td><td rowspan="1" colspan="1">25 (100%)</td><td rowspan="1" colspan="1">204 (99%)</td><td rowspan="1" colspan="1">1.000</td></tr><tr><td rowspan="1" colspan="1">Aztreonam</td><td rowspan="1" colspan="1">25 (100%)</td><td rowspan="1" colspan="1">206 (100%)</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Ertapenem</td><td rowspan="1" colspan="1">25 (100%)</td><td rowspan="1" colspan="1">206 (100%)</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Imipenem</td><td rowspan="1" colspan="1">25 (100%)</td><td rowspan="1" colspan="1">206 (100%)</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Meropenem</td><td rowspan="1" colspan="1">25 (100%)</td><td rowspan="1" colspan="1">206 (100%)</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Amikacin</td><td rowspan="1" colspan="1">24 (96%)</td><td rowspan="1" colspan="1">140 (68%)</td><td rowspan="1" colspan="1">0.004*</td></tr><tr><td rowspan="1" colspan="1">Tobramycin</td><td rowspan="1" colspan="1">24 (96%)</td><td rowspan="1" colspan="1">167 (81.1%)</td><td rowspan="1" colspan="1">0.113</td></tr><tr><td rowspan="1" colspan="1">Ciprofloxacin</td><td rowspan="1" colspan="1">25 (100%)</td><td rowspan="1" colspan="1">205 (99.5%)</td><td rowspan="1" colspan="1">1.000</td></tr><tr><td rowspan="1" colspan="1">Levofloxacin</td><td rowspan="1" colspan="1">25 (100%)</td><td rowspan="1" colspan="1">204 (99%)</td><td rowspan="1" colspan="1">1.000</td></tr><tr><td rowspan="1" colspan="1">Doxycycline</td><td rowspan="1" colspan="1">11 (44%)</td><td rowspan="1" colspan="1">168 (81.6%)</td><td rowspan="1" colspan="1">&lt; 0.001*</td></tr><tr><td rowspan="1" colspan="1">Minocycline</td><td rowspan="1" colspan="1">16 (64%)</td><td rowspan="1" colspan="1">165 (80.1%)</td><td rowspan="1" colspan="1">0.065</td></tr><tr><td rowspan="1" colspan="1">Tigecycline</td><td rowspan="1" colspan="1">8 (32%)</td><td rowspan="1" colspan="1">73 (35.4%)</td><td rowspan="1" colspan="1">0.734</td></tr><tr><td rowspan="1" colspan="1">Colistin</td><td rowspan="1" colspan="1">3 (12%)</td><td rowspan="1" colspan="1">20 (9.7%)</td><td rowspan="1" colspan="1">0.994</td></tr><tr><td rowspan="1" colspan="1">Trimethoprim-sulfamethoxazole</td><td rowspan="1" colspan="1">25 (100%)</td><td rowspan="1" colspan="1">110 (53.4%)</td><td rowspan="1" colspan="1">&lt; 0.001*</td></tr></tbody></table><table-wrap-foot><fn id="tfn0005"><p><bold>Notes</bold>: Data are presented as No. (%) of patients. *<italic toggle="yes">P</italic> &lt; 0.05, the comparison between KPC-NDM-CRKPs and KPC-CRKPs.</p></fn><fn id="tfn0006"><p><bold>Abbreviations</bold>: KPC, <italic toggle="yes">Klebsiella pneumoniae</italic> carbapenemase; NDM, New Delhi metallo-&#x3B2;-lactamase; CRKP, carbapenem-resistant <italic toggle="yes">Klebsiella pneumoniae</italic>; KPC-NDM-CRKP, KPC and NDM co-producing carbapenem-resistant <italic toggle="yes">Klebsiella pneumoniae</italic>; KPC-CRKP, KPC-producing carbapenem-resistant <italic toggle="yes">Klebsiella pneumoniae</italic>; NA, not available.</p></fn></table-wrap-foot></table-wrap>
</p>
      </sec>
      <sec id="s0003-s2004">
        <title>Molecular Characteristics of KPC-NDM-CRKP and KPC-CRKP Isolates</title>
        <p>Among the 231 CRKP isolates, nine STs were represented. The most prevalent ST in KPC-NDM-CRKP isolates was ST11 (23/25, 92%), followed by ST15 (2/25, 8%). In KPC-CRKP isolates, ST11 was the most dominant, with a prevalence of 82.5% (n = 170), followed by ST15 (13.6%, 28/206), ST2237 (n = 2), ST17 (n = 1), ST111 (n = 1), ST551 (n = 1), ST1027 (n = 1), ST2286 (n = 1), and ST5422 (n = 1). The majority of KPC-NDM-CRKP isolates were KPC-2-NDM-5-CRKP (n = 22, 88%), with KPC-2-NDM-1-CRKP (n = 3, 12%) being the next most common. The <italic toggle="yes">bla</italic><sub>KPC-2</sub> gene was detected in 205 (99.5%) out of 206 KPC-CRKP isolates and only one isolate carried the <italic toggle="yes">bla</italic><sub>KPC-12</sub> gene (<underline><ext-link xlink:href="https://www.dovepress.com/get_supplementary_file.php?f=455146.pdf" ext-link-type="uri">Supplementary Figure 2</ext-link></underline>).</p>
      </sec>
      <sec id="s0003-s2005">
        <title>Outcome Study</title>
        <p>The overall 30-day mortality rate was 35.1% (81/231). KPC-NDM-CRKP and KPC-CRKP BSIs had 30-day mortality rates of 56% (14/25) and 32.5% (67/206), respectively (<italic toggle="yes">P</italic> = 0.02). Identification of clinical characteristics and microbiological features associated with 30-day mortality was also performed in both the KPC-NDM-CRKP BSIs group and the KPC-CRKP BSIs group. As presented in <xref rid="t0004" ref-type="table">Table 4</xref>, age (<italic toggle="yes">P</italic> = 0.001), ICU-acquired BSIs (<italic toggle="yes">P</italic> &lt; 0.001), underlying disease with hypertension (<italic toggle="yes">P</italic> &lt; 0.001) or biliary tract disease (<italic toggle="yes">P</italic> = 0.034), laboratory data including PCT (<italic toggle="yes">P</italic> &lt; 0.001), CRP (<italic toggle="yes">P</italic> &lt; 0.001), platelet count (<italic toggle="yes">P</italic> &lt; 0.001), and NEUT% (<italic toggle="yes">P</italic> &lt; 0.001) at BSI onset, the length of full hospital stay (<italic toggle="yes">P</italic> &lt; 0.001) and ICU stay (<italic toggle="yes">P</italic> = 0.006), the APACHE II score (<italic toggle="yes">P</italic> &lt; 0.001) and the Pitt bacteremia score (<italic toggle="yes">P</italic> &lt; 0.001) at BSI onset, the presence of sepsis or septic shock at BSI onset (<italic toggle="yes">P</italic> &lt; 0.001), BSIs caused by KPC-NDM-CRKP (<italic toggle="yes">P</italic> = 0.02), empirical combination antimicrobial therapy (<italic toggle="yes">P</italic> = 0.003), colistin-containing empirical treatment (<italic toggle="yes">P</italic> = 0.007), and inappropriate empirical treatment (<italic toggle="yes">P</italic> = 0.005) were associated with 30-day mortality in the cases of CRKP BSIs.<table-wrap position="float" id="t0004" orientation="landscape"><label>Table 4</label><caption><p>Clinical and Microbiological Characteristics Associated with 30-Day Mortality of CRKP BSIs</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1">Characteristics</th><th colspan="3" align="center" rowspan="1">All CRKP BSIs</th><th colspan="3" align="center" rowspan="1">KPC-NDM-CRKP BSIs</th><th colspan="3" align="center" rowspan="1">KPC-CRKP BSIs</th></tr><tr><th rowspan="1" colspan="1">Death (n=81)</th><th rowspan="1" colspan="1">Survivors (n=150)</th><th rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th><th rowspan="1" colspan="1">Death (n=14)</th><th rowspan="1" colspan="1">Survivors (n=11)</th><th rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th><th rowspan="1" colspan="1">Death (n=67)</th><th rowspan="1" colspan="1">Survivors (n=139)</th><th rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age, years, mean &#xB1; SD</td><td rowspan="1" colspan="1">56.8 &#xB1; 13.4</td><td rowspan="1" colspan="1">49.9 &#xB1; 15.8</td><td rowspan="1" colspan="1">0.001*</td><td rowspan="1" colspan="1">56.6 &#xB1; 10.7</td><td rowspan="1" colspan="1">51.2 &#xB1; 14.1</td><td rowspan="1" colspan="1">0.280</td><td rowspan="1" colspan="1">56.8 &#xB1; 14</td><td rowspan="1" colspan="1">49.8 &#xB1; 15.9</td><td rowspan="1" colspan="1">0.002*</td></tr><tr><td rowspan="1" colspan="1">Male sex</td><td rowspan="1" colspan="1">65 (80.2%)</td><td rowspan="1" colspan="1">112 (74.7%)</td><td rowspan="1" colspan="1">0.339</td><td rowspan="1" colspan="1">11 (78.6%)</td><td rowspan="1" colspan="1">10 (90.9%)</td><td rowspan="1" colspan="1">0.775</td><td rowspan="1" colspan="1">54 (80.6%)</td><td rowspan="1" colspan="1">102 (73.4%)</td><td rowspan="1" colspan="1">0.258</td></tr><tr><td rowspan="1" colspan="1"><bold>Acquisition</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x2003;Community-acquired</td><td rowspan="1" colspan="1">1 (1.2%)</td><td rowspan="1" colspan="1">5 (3.3%)</td><td rowspan="1" colspan="1">0.601</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">1 (1.5%)</td><td rowspan="1" colspan="1">5 (3.6%)</td><td rowspan="1" colspan="1">0.690</td></tr><tr><td rowspan="1" colspan="1">&#x2003;ICU-acquired</td><td rowspan="1" colspan="1">65 (80.2%)</td><td rowspan="1" colspan="1">75 (50.0%)</td><td rowspan="1" colspan="1">&lt; 0.001*</td><td rowspan="1" colspan="1">13 (92.9%)</td><td rowspan="1" colspan="1">8 (72.7%)</td><td rowspan="1" colspan="1">0.416</td><td rowspan="1" colspan="1">52 (77.6%)</td><td rowspan="1" colspan="1">67 (48.2%)</td><td rowspan="1" colspan="1">&lt; 0.001*</td></tr><tr><td rowspan="1" colspan="1"><bold>Underlying conditions</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x2003;Solid cancer</td><td rowspan="1" colspan="1">10 (12.3%)</td><td rowspan="1" colspan="1">20 (13.3%)</td><td rowspan="1" colspan="1">0.831</td><td rowspan="1" colspan="1">1 (7.1%)</td><td rowspan="1" colspan="1">2 (18.2%)</td><td rowspan="1" colspan="1">0.823</td><td rowspan="1" colspan="1">9 (13.4%)</td><td rowspan="1" colspan="1">18 (12.9%)</td><td rowspan="1" colspan="1">0.923</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Hypertension</td><td rowspan="1" colspan="1">39 (48.1%)</td><td rowspan="1" colspan="1">37 (24.7%)</td><td rowspan="1" colspan="1">&lt; 0.001*</td><td rowspan="1" colspan="1">9 (64.3%)</td><td rowspan="1" colspan="1">3 (27.3%)</td><td rowspan="1" colspan="1">0.066</td><td rowspan="1" colspan="1">30 (44.8%)</td><td rowspan="1" colspan="1">34 (24.5%)</td><td rowspan="1" colspan="1">0.003*</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Cardiovascular disease</td><td rowspan="1" colspan="1">16 (19.8%)</td><td rowspan="1" colspan="1">18 (12.0%)</td><td rowspan="1" colspan="1">0.112</td><td rowspan="1" colspan="1">2 (14.3%)</td><td rowspan="1" colspan="1">2 (18.2%)</td><td rowspan="1" colspan="1">1.000</td><td rowspan="1" colspan="1">14 (20.9%)</td><td rowspan="1" colspan="1">16 (11.5%)</td><td rowspan="1" colspan="1">0.074</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Neurologic disorder</td><td rowspan="1" colspan="1">16 (19.8%)</td><td rowspan="1" colspan="1">23 (15.3%)</td><td rowspan="1" colspan="1">0.392</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1 (9.1%)</td><td rowspan="1" colspan="1">0.440</td><td rowspan="1" colspan="1">16 (23.9%)</td><td rowspan="1" colspan="1">22 (15.8%)</td><td rowspan="1" colspan="1">0.163</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Diabetes mellitus</td><td rowspan="1" colspan="1">15 (18.5%)</td><td rowspan="1" colspan="1">36 (24.0%)</td><td rowspan="1" colspan="1">0.338</td><td rowspan="1" colspan="1">2 (14.3%)</td><td rowspan="1" colspan="1">1 (9.1%)</td><td rowspan="1" colspan="1">1.000</td><td rowspan="1" colspan="1">13 (19.4%)</td><td rowspan="1" colspan="1">35 (25.2%)</td><td rowspan="1" colspan="1">0.358</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Gastrointestinal fistula</td><td rowspan="1" colspan="1">34 (42.0%)</td><td rowspan="1" colspan="1">57 (38.0%)</td><td rowspan="1" colspan="1">0.555</td><td rowspan="1" colspan="1">6 (42.9%)</td><td rowspan="1" colspan="1">6 (54.5%)</td><td rowspan="1" colspan="1">0.561</td><td rowspan="1" colspan="1">28 (41.8%)</td><td rowspan="1" colspan="1">51 (36.7%)</td><td rowspan="1" colspan="1">0.481</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Chronic renal failure</td><td rowspan="1" colspan="1">8 (9.9%)</td><td rowspan="1" colspan="1">7 (4.7%)</td><td rowspan="1" colspan="1">0.125</td><td rowspan="1" colspan="1">1 (7.1%)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1.000</td><td rowspan="1" colspan="1">7 (10.4%)</td><td rowspan="1" colspan="1">7 (5.0%)</td><td rowspan="1" colspan="1">0.250</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Fatty liver</td><td rowspan="1" colspan="1">5 (6.2%)</td><td rowspan="1" colspan="1">21 (14.0%)</td><td rowspan="1" colspan="1">0.072</td><td rowspan="1" colspan="1">1 (7.1%)</td><td rowspan="1" colspan="1">1 (9.1%)</td><td rowspan="1" colspan="1">1.000</td><td rowspan="1" colspan="1">4 (6%)</td><td rowspan="1" colspan="1">20 (14.4%)</td><td rowspan="1" colspan="1">0.078</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Chronic liver disease</td><td rowspan="1" colspan="1">8 (9.9%)</td><td rowspan="1" colspan="1">14 (9.3%)</td><td rowspan="1" colspan="1">0.893</td><td rowspan="1" colspan="1">2 (14.3%)</td><td rowspan="1" colspan="1">1 (9.1%)</td><td rowspan="1" colspan="1">1.000</td><td rowspan="1" colspan="1">6 (9%)</td><td rowspan="1" colspan="1">13 (9.4%)</td><td rowspan="1" colspan="1">0.926</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Biliary tract disease</td><td rowspan="1" colspan="1">35 (43.2%)</td><td rowspan="1" colspan="1">44 (29.3%)</td><td rowspan="1" colspan="1">0.034*</td><td rowspan="1" colspan="1">6 (42.9%)</td><td rowspan="1" colspan="1">2 (18.2%)</td><td rowspan="1" colspan="1">0.378</td><td rowspan="1" colspan="1">29 (43.3%)</td><td rowspan="1" colspan="1">42 (30.2%)</td><td rowspan="1" colspan="1">0.064</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Malnutrition</td><td rowspan="1" colspan="1">12 (14.8%)</td><td rowspan="1" colspan="1">17 (11.3%)</td><td rowspan="1" colspan="1">0.446</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2 (18.2%)</td><td rowspan="1" colspan="1">0.183</td><td rowspan="1" colspan="1">12 (17.9%)</td><td rowspan="1" colspan="1">15 (10.8%)</td><td rowspan="1" colspan="1">0.156</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Trauma</td><td rowspan="1" colspan="1">11 (13.6%)</td><td rowspan="1" colspan="1">23 (15.3%)</td><td rowspan="1" colspan="1">0.720</td><td rowspan="1" colspan="1">2 (14.3%)</td><td rowspan="1" colspan="1">4 (36.4%)</td><td rowspan="1" colspan="1">0.417</td><td rowspan="1" colspan="1">9 (13.4%)</td><td rowspan="1" colspan="1">19 (13.7%)</td><td rowspan="1" colspan="1">0.963</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Surgery within 30 days</td><td rowspan="1" colspan="1">33 (40.7%)</td><td rowspan="1" colspan="1">59 (39.3%)</td><td rowspan="1" colspan="1">0.835</td><td rowspan="1" colspan="1">7 (50%)</td><td rowspan="1" colspan="1">7 (63.6%)</td><td rowspan="1" colspan="1">0.783</td><td rowspan="1" colspan="1">26 (38.8%)</td><td rowspan="1" colspan="1">52 (37.4%)</td><td rowspan="1" colspan="1">0.847</td></tr><tr><td rowspan="1" colspan="1"><bold>Source of BSI</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x2003;Respiratory tract</td><td rowspan="1" colspan="1">19 (23.5%)</td><td rowspan="1" colspan="1">21 (14.0%)</td><td rowspan="1" colspan="1">0.070</td><td rowspan="1" colspan="1">1 (7.1%)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1.000</td><td rowspan="1" colspan="1">18 (26.9%)</td><td rowspan="1" colspan="1">21 (15.1%)</td><td rowspan="1" colspan="1">0.044*</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Abdomen</td><td rowspan="1" colspan="1">61 (75.3%)</td><td rowspan="1" colspan="1">116 (77.3%)</td><td rowspan="1" colspan="1">0.729</td><td rowspan="1" colspan="1">13 (92.9%)</td><td rowspan="1" colspan="1">9 (81.8%)</td><td rowspan="1" colspan="1">0.823</td><td rowspan="1" colspan="1">48 (71.6%)</td><td rowspan="1" colspan="1">107 (77.0%)</td><td rowspan="1" colspan="1">0.406</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Urinary tract</td><td rowspan="1" colspan="1">1 (1.2%)</td><td rowspan="1" colspan="1">9 (6.0%)</td><td rowspan="1" colspan="1">0.174</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1 (9.1%)</td><td rowspan="1" colspan="1">0.440</td><td rowspan="1" colspan="1">1 (1.5%)</td><td rowspan="1" colspan="1">8 (5.8%)</td><td rowspan="1" colspan="1">0.299</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Skin and soft tissue</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">4 (2.7%)</td><td rowspan="1" colspan="1">0.340</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1 (9.1%)</td><td rowspan="1" colspan="1">0.440</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">3 (2.2%)</td><td rowspan="1" colspan="1">0.552</td></tr><tr><td rowspan="1" colspan="1"><bold>Infection and microbiological data</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x2003;WBC count, &#xD7;10<sup>9</sup>/L, median (IQR)</td><td rowspan="1" colspan="1">10.8 (7.4&#x2013;17.2)</td><td rowspan="1" colspan="1">9.2 (6.3&#x2013;14.4)</td><td rowspan="1" colspan="1">0.222</td><td rowspan="1" colspan="1">9.7 (4.5&#x2013;19.9)</td><td rowspan="1" colspan="1">9.2 (5.1&#x2013;17.5)</td><td rowspan="1" colspan="1">0.979</td><td rowspan="1" colspan="1">10.8 (7.5&#x2013;16)</td><td rowspan="1" colspan="1">9.3 (6.3&#x2013;14.3)</td><td rowspan="1" colspan="1">0.163</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Albumin, g/L, mean &#xB1; SD</td><td rowspan="1" colspan="1">31.6 &#xB1; 5.5</td><td rowspan="1" colspan="1">31.2 &#xB1; 4.6</td><td rowspan="1" colspan="1">0.563</td><td rowspan="1" colspan="1">31.4 &#xB1; 5.5</td><td rowspan="1" colspan="1">30.7 &#xB1; 3.5</td><td rowspan="1" colspan="1">0.695</td><td rowspan="1" colspan="1">31.6 &#xB1; 5.6</td><td rowspan="1" colspan="1">31.2 &#xB1; 4.7</td><td rowspan="1" colspan="1">0.602</td></tr><tr><td rowspan="1" colspan="1">&#x2003;PCT, &#x3BC;g/L, median (IQR)</td><td rowspan="1" colspan="1">9.2 (2.7&#x2013;25.1)</td><td rowspan="1" colspan="1">2.1 (0.7&#x2013;13.5)</td><td rowspan="1" colspan="1">&lt; 0.001*</td><td rowspan="1" colspan="1">13.4 (6.5&#x2013;36.9)</td><td rowspan="1" colspan="1">5.7 (0.7&#x2013;13.5)</td><td rowspan="1" colspan="1">0.120</td><td rowspan="1" colspan="1">7.7 (2.6&#x2013;24.8)</td><td rowspan="1" colspan="1">1.9 (0.7&#x2013;13.5)</td><td rowspan="1" colspan="1">&lt; 0.001*</td></tr><tr><td rowspan="1" colspan="1">&#x2003;CRP, mg/L, median (IQR)</td><td rowspan="1" colspan="1">182.4 (128&#x2013;250.7)</td><td rowspan="1" colspan="1">129.6 (66.9&#x2013;182.4)</td><td rowspan="1" colspan="1">&lt; 0.001*</td><td rowspan="1" colspan="1">184.6 (136.3&#x2013;250.6)</td><td rowspan="1" colspan="1">67.7 (39.8&#x2013;154.1)</td><td rowspan="1" colspan="1">0.014*</td><td rowspan="1" colspan="1">180 (127.4&#x2013;252.6)</td><td rowspan="1" colspan="1">130.7 (70.7&#x2013;184.2)</td><td rowspan="1" colspan="1">&lt; 0.001*</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Platelet count, &#xD7;10<sup>9</sup>/L, median (IQR)</td><td rowspan="1" colspan="1">94 (44&#x2013;169.5)</td><td rowspan="1" colspan="1">206 (108.5&#x2013;277.8)</td><td rowspan="1" colspan="1">&lt; 0.001*</td><td rowspan="1" colspan="1">81 (37.8&#x2013;179.8)</td><td rowspan="1" colspan="1">231 (76&#x2013;401)</td><td rowspan="1" colspan="1">0.051</td><td rowspan="1" colspan="1">94 (49&#x2013;170)</td><td rowspan="1" colspan="1">205 (110&#x2013;277)</td><td rowspan="1" colspan="1">&lt; 0.001*</td></tr><tr><td rowspan="1" colspan="1">&#x2003;NEUT%, median (IQR)</td><td rowspan="1" colspan="1">91.2 (86.5&#x2013;94.2)</td><td rowspan="1" colspan="1">87.1 (81.4&#x2013;92.2)</td><td rowspan="1" colspan="1">&lt; 0.001*</td><td rowspan="1" colspan="1">91.7 (85.6&#x2013;94.5)</td><td rowspan="1" colspan="1">82.6 (74.5&#x2013;93)</td><td rowspan="1" colspan="1">0.166</td><td rowspan="1" colspan="1">91.1 (86.6&#x2013;93.9)</td><td rowspan="1" colspan="1">87.3 (82.2&#x2013;92.1)</td><td rowspan="1" colspan="1">&lt; 0.001*</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Hospital stay prior to CRKP isolation, median (IQR)</td><td rowspan="1" colspan="1">16 (9&#x2013;25.5)</td><td rowspan="1" colspan="1">15 (4&#x2013;26.2)</td><td rowspan="1" colspan="1">0.416</td><td rowspan="1" colspan="1">18 (10.2&#x2013;32)</td><td rowspan="1" colspan="1">25 (7&#x2013;33)</td><td rowspan="1" colspan="1">0.767</td><td rowspan="1" colspan="1">15 (8&#x2013;25)</td><td rowspan="1" colspan="1">15 (4&#x2013;25)</td><td rowspan="1" colspan="1">0.483</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Full hospital stay, median (IQR)</td><td rowspan="1" colspan="1">28 (18&#x2013;37.5)</td><td rowspan="1" colspan="1">54.5 (34.8&#x2013;82.2)</td><td rowspan="1" colspan="1">&lt; 0.001*</td><td rowspan="1" colspan="1">24.5 (17.2&#x2013;41.8)</td><td rowspan="1" colspan="1">83 (43&#x2013;140)</td><td rowspan="1" colspan="1">0.004*</td><td rowspan="1" colspan="1">29 (18&#x2013;38)</td><td rowspan="1" colspan="1">54 (34&#x2013;76)</td><td rowspan="1" colspan="1">&lt; 0.001*</td></tr><tr><td rowspan="1" colspan="1">&#x2003;ICU stay, median (IQR)</td><td rowspan="1" colspan="1">24 (13&#x2013;35)</td><td rowspan="1" colspan="1">37 (13&#x2013;63.5)</td><td rowspan="1" colspan="1">0.006*</td><td rowspan="1" colspan="1">24.5 (17.2&#x2013;39)</td><td rowspan="1" colspan="1">50 (19&#x2013;121)</td><td rowspan="1" colspan="1">0.120</td><td rowspan="1" colspan="1">24 (11&#x2013;35)</td><td rowspan="1" colspan="1">33 (12&#x2013;62)</td><td rowspan="1" colspan="1">0.011*</td></tr><tr><td rowspan="1" colspan="1">&#x2003;APACHE II score at infection onset, median (IQR)</td><td rowspan="1" colspan="1">19 (16.5&#x2013;23)</td><td rowspan="1" colspan="1">9 (6&#x2013;12)</td><td rowspan="1" colspan="1">&lt; 0.001*</td><td rowspan="1" colspan="1">19 (16.8&#x2013;23)</td><td rowspan="1" colspan="1">6 (4&#x2013;13)</td><td rowspan="1" colspan="1">&lt; 0.001*</td><td rowspan="1" colspan="1">18 (16&#x2013;23)</td><td rowspan="1" colspan="1">9 (6&#x2013;12)</td><td rowspan="1" colspan="1">&lt; 0.001*</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Pitt bacteremia score at infection onset, median (IQR)</td><td rowspan="1" colspan="1">5 (3&#x2013;7)</td><td rowspan="1" colspan="1">1.5 (0&#x2013;3)</td><td rowspan="1" colspan="1">&lt; 0.001*</td><td rowspan="1" colspan="1">5 (4&#x2013;8)</td><td rowspan="1" colspan="1">2 (0&#x2013;3)</td><td rowspan="1" colspan="1">&lt; 0.001*</td><td rowspan="1" colspan="1">4 (3&#x2013;6)</td><td rowspan="1" colspan="1">1 (0&#x2013;3)</td><td rowspan="1" colspan="1">&lt; 0.001*</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Sepsis/septic shock at infection onset</td><td rowspan="1" colspan="1">68 (84.0%)</td><td rowspan="1" colspan="1">53 (35.3%)</td><td rowspan="1" colspan="1">&lt; 0.001*</td><td rowspan="1" colspan="1">12 (85.7%)</td><td rowspan="1" colspan="1">4 (36.4%)</td><td rowspan="1" colspan="1">0.033*</td><td rowspan="1" colspan="1">56 (83.6%)</td><td rowspan="1" colspan="1">49 (35.3%)</td><td rowspan="1" colspan="1">&lt; 0.001*</td></tr><tr><td rowspan="1" colspan="1">&#x2003;KPC-NDM-CRKP</td><td rowspan="1" colspan="1">14 (17.3%)</td><td rowspan="1" colspan="1">11 (7.3%)</td><td rowspan="1" colspan="1">0.020*</td><td rowspan="1" colspan="1">&#x2014;</td><td rowspan="1" colspan="1">&#x2014;</td><td rowspan="1" colspan="1">&#x2014;</td><td rowspan="1" colspan="1">&#x2014;</td><td rowspan="1" colspan="1">&#x2014;</td><td rowspan="1" colspan="1">&#x2014;</td></tr><tr><td rowspan="1" colspan="1"><bold>Empirical therapy</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x2003;Combination therapy</td><td rowspan="1" colspan="1">65 (80.2%)</td><td rowspan="1" colspan="1">92 (61.3%)</td><td rowspan="1" colspan="1">0.003*</td><td rowspan="1" colspan="1">13 (92.9%)</td><td rowspan="1" colspan="1">7 (63.6%)</td><td rowspan="1" colspan="1">0.190</td><td rowspan="1" colspan="1">52 (77.6%)</td><td rowspan="1" colspan="1">85 (61.2%)</td><td rowspan="1" colspan="1">0.019*</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Carbapenem-containing regimens</td><td rowspan="1" colspan="1">66 (81.5%)</td><td rowspan="1" colspan="1">111 (74.0%)</td><td rowspan="1" colspan="1">0.200</td><td rowspan="1" colspan="1">9 (64.3%)</td><td rowspan="1" colspan="1">7 (63.6%)</td><td rowspan="1" colspan="1">1.000</td><td rowspan="1" colspan="1">57 (85.1%)</td><td rowspan="1" colspan="1">104 (74.8%)</td><td rowspan="1" colspan="1">0.095</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Tigecycline-containing regimens</td><td rowspan="1" colspan="1">32 (39.5%)</td><td rowspan="1" colspan="1">43 (28.7%)</td><td rowspan="1" colspan="1">0.093</td><td rowspan="1" colspan="1">4 (28.6%)</td><td rowspan="1" colspan="1">5 (45.5%)</td><td rowspan="1" colspan="1">0.650</td><td rowspan="1" colspan="1">28 (41.8%)</td><td rowspan="1" colspan="1">38 (27.3%)</td><td rowspan="1" colspan="1">0.037*</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Colistin-containing regimens</td><td rowspan="1" colspan="1">28 (34.6%)</td><td rowspan="1" colspan="1">28 (18.7%)</td><td rowspan="1" colspan="1">0.007*</td><td rowspan="1" colspan="1">6 (42.9%)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.043*</td><td rowspan="1" colspan="1">22 (32.8%)</td><td rowspan="1" colspan="1">28 (20.1%)</td><td rowspan="1" colspan="1">0.047*</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Ceftazidime-avibactam-containing regimens</td><td rowspan="1" colspan="1">13 (16.0%)</td><td rowspan="1" colspan="1">13 (8.7%)</td><td rowspan="1" colspan="1">0.090</td><td rowspan="1" colspan="1">4 (28.6%)</td><td rowspan="1" colspan="1">2 (18.2%)</td><td rowspan="1" colspan="1">0.895</td><td rowspan="1" colspan="1">9 (13.4%)</td><td rowspan="1" colspan="1">11 (7.9%)</td><td rowspan="1" colspan="1">0.210</td></tr><tr><td rowspan="1" colspan="1">&#x2003;Inappropriate empirical treatment</td><td rowspan="1" colspan="1">37 (45.7%)</td><td rowspan="1" colspan="1">97 (64.7%)</td><td rowspan="1" colspan="1">0.005*</td><td rowspan="1" colspan="1">6 (42.9%)</td><td rowspan="1" colspan="1">8 (72.7%)</td><td rowspan="1" colspan="1">0.277</td><td rowspan="1" colspan="1">31 (46.3%)</td><td rowspan="1" colspan="1">89 (64%)</td><td rowspan="1" colspan="1">0.015*</td></tr></tbody></table><table-wrap-foot><fn id="tfn0007"><p><bold>Notes</bold>: Data are presented as No. (%) of patients unless otherwise specified. *<italic toggle="yes">P</italic> &lt; 0.05 compared with survivors.</p></fn><fn id="tfn0008"><p><bold>Abbreviations</bold>: KPC, <italic toggle="yes">Klebsiella pneumoniae</italic> carbapenemase; NDM, New Delhi metallo-&#x3B2;-lactamase; CRKP, carbapenem-resistant <italic toggle="yes">Klebsiella pneumoniae</italic>; KPC-NDM-CRKP, KPC and NDM co-producing carbapenem-resistant <italic toggle="yes">Klebsiella pneumoniae</italic>; KPC-CRKP, KPC-producing carbapenem-resistant <italic toggle="yes">Klebsiella pneumoniae</italic>; BSI, bloodstream infection; ICU, intensive care unit; WBC, white blood cell; PCT, procalcitonin; CRP, C-reactive protein; NEUT%, neutrophilic granulocyte percentage; APACHE, acute physiologic and chronic health evaluation; SD, standard deviation; IQR, interquartile range; NA, not available.</p></fn></table-wrap-foot></table-wrap>
</p>
        <p>Univariate analysis demonstrated that older age (95% CI 1.012&#x2013;1.051; <italic toggle="yes">P</italic> = 0.001), hypertension (95% CI 1.600&#x2013;5.027; <italic toggle="yes">P</italic> &lt; 0.001), biliary tract disease (95% CI 1.044&#x2013;3.218; <italic toggle="yes">P</italic> = 0.035), higher levels of inflammation markers at BSI onset including PCT (95% CI 1.009&#x2013;1.037; <italic toggle="yes">P</italic> = 0.001), CRP (95% CI 1.005&#x2013;1.012; <italic toggle="yes">P</italic> &lt; 0.001), NEUT% (95% CI 1.040&#x2013;1.143; <italic toggle="yes">P</italic> &lt; 0.001), and platelet count (95% CI 0.990&#x2013;0.996; <italic toggle="yes">P</italic> &lt; 0.001), ICU-acquired BSIs (95% CI 2.156&#x2013;7.656; <italic toggle="yes">P</italic> &lt; 0.001), BSIs caused by KPC-NDM-CRKPs (95% CI 1.138&#x2013;6.127; <italic toggle="yes">P</italic> = 0.024), higher APACHE II score at infection onset (95% CI 1.256&#x2013;1.458; <italic toggle="yes">P</italic> &lt; 0.001), higher Pitt bacteremia score at infection onset (95% CI 1.383&#x2013;1.810; <italic toggle="yes">P</italic> &lt; 0.001), the presence of sepsis or septic shock at infection onset (95% CI 4.844&#x2013;18.920; <italic toggle="yes">P</italic> &lt; 0.001), empirical combination antimicrobial therapy (95% CI 1.353&#x2013;4.848; <italic toggle="yes">P</italic> = 0.004), colistin-containing empirical treatment (95% CI 1.244&#x2013;4.258; <italic toggle="yes">P</italic> = 0.008), and inappropriate empirical treatment (95% CI 0.265&#x2013;0.797; <italic toggle="yes">P</italic> = 0.006) were associated with 30-day mortality (<xref rid="t0005" ref-type="table">Table 5</xref>).<table-wrap position="float" id="t0005"><label>Table 5</label><caption><p>Multivariate Analysis for Predictors of 30-Day Mortality in Patients with CRKP BSIs</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1">Variables</th><th colspan="2" rowspan="1">Univariate Analysis</th><th colspan="2" rowspan="1">Multivariate Analysis</th></tr><tr><th rowspan="1" colspan="1">OR (95% CI)</th><th rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th><th rowspan="1" colspan="1">OR (95% CI)</th><th rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age</td><td rowspan="1" colspan="1">1.031 (1.012&#x2013;1.051)</td><td rowspan="1" colspan="1">0.001*</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">ICU-acquired</td><td rowspan="1" colspan="1">4.062 (2.156&#x2013;7.656)</td><td rowspan="1" colspan="1">&lt; 0.001*</td><td rowspan="1" colspan="1">10.216 (2.707&#x2013;38.559)</td><td rowspan="1" colspan="1">0.001*</td></tr><tr><td rowspan="1" colspan="1">Hypertension</td><td rowspan="1" colspan="1">2.836 (1.600&#x2013;5.027)</td><td rowspan="1" colspan="1">&lt; 0.001*</td><td rowspan="1" colspan="1">2.705 (0.974&#x2013;7.511)</td><td rowspan="1" colspan="1">0.056</td></tr><tr><td rowspan="1" colspan="1">Fatty liver</td><td rowspan="1" colspan="1">0.404 (0.146&#x2013;1.116)</td><td rowspan="1" colspan="1">0.080</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Biliary tract disease</td><td rowspan="1" colspan="1">1.833 (1.044&#x2013;3.218)</td><td rowspan="1" colspan="1">0.035*</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Respiratory tract</td><td rowspan="1" colspan="1">1.882 (0.944&#x2013;3.755)</td><td rowspan="1" colspan="1">0.073</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">PCT</td><td rowspan="1" colspan="1">1.023 (1.009&#x2013;1.037)</td><td rowspan="1" colspan="1">0.001*</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">CRP</td><td rowspan="1" colspan="1">1.008 (1.005&#x2013;1.012)</td><td rowspan="1" colspan="1">&lt; 0.001*</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Platelet count</td><td rowspan="1" colspan="1">0.993 (0.990&#x2013;0.996)</td><td rowspan="1" colspan="1">&lt; 0.001*</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">NEUT%</td><td rowspan="1" colspan="1">1.090 (1.040&#x2013;1.143)</td><td rowspan="1" colspan="1">&lt; 0.001*</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Full hospital stay</td><td rowspan="1" colspan="1">0.958 (0.944&#x2013;0.972)</td><td rowspan="1" colspan="1">&lt; 0.001*</td><td rowspan="1" colspan="1">0.967 (0.937&#x2013;0.999)</td><td rowspan="1" colspan="1">0.043*</td></tr><tr><td rowspan="1" colspan="1">ICU stay</td><td rowspan="1" colspan="1">0.981 (0.971&#x2013;0.992)</td><td rowspan="1" colspan="1">0.001*</td><td rowspan="1" colspan="1">0.958 (0.921&#x2013;0.996)</td><td rowspan="1" colspan="1">0.030*</td></tr><tr><td rowspan="1" colspan="1">APACHE II score at infection onset</td><td rowspan="1" colspan="1">1.353 (1.256&#x2013;1.458)</td><td rowspan="1" colspan="1">&lt; 0.001*</td><td rowspan="1" colspan="1">1.435 (1.288&#x2013;1.599)</td><td rowspan="1" colspan="1">&lt; 0.001*</td></tr><tr><td rowspan="1" colspan="1">Pitt bacteremia score at infection onset</td><td rowspan="1" colspan="1">1.582 (1.383&#x2013;1.810)</td><td rowspan="1" colspan="1">&lt; 0.001*</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Sepsis/septic shock at infection onset</td><td rowspan="1" colspan="1">9.573 (4.844&#x2013;18.920)</td><td rowspan="1" colspan="1">&lt; 0.001*</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">KPC-NDM-CRKP</td><td rowspan="1" colspan="1">2.640 (1.138&#x2013;6.127)</td><td rowspan="1" colspan="1">0.024*</td><td rowspan="1" colspan="1">8.355 (1.103&#x2013;63.270)</td><td rowspan="1" colspan="1">0.040*</td></tr><tr><td rowspan="1" colspan="1">Combination therapy</td><td rowspan="1" colspan="1">2.561 (1.353&#x2013;4.848)</td><td rowspan="1" colspan="1">0.004*</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Tigecycline-containing regimens</td><td rowspan="1" colspan="1">1.625 (0.920&#x2013;2.870)</td><td rowspan="1" colspan="1">0.094</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Colistin-containing regimens</td><td rowspan="1" colspan="1">2.302 (1.244&#x2013;4.258)</td><td rowspan="1" colspan="1">0.008*</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Ceftazidime-avibactam-containing regimens</td><td rowspan="1" colspan="1">2.015 (0.886&#x2013;4.583)</td><td rowspan="1" colspan="1">0.095</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Inappropriate empirical treatment</td><td rowspan="1" colspan="1">0.459 (0.265&#x2013;0.797)</td><td rowspan="1" colspan="1">0.006*</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tfn0009"><p><bold>Notes</bold>: *<italic toggle="yes">P</italic> &lt; 0.05.</p></fn><fn id="tfn0010"><p><bold>Abbreviations</bold>: KPC, <italic toggle="yes">Klebsiella pneumoniae</italic> carbapenemase; NDM, New Delhi metallo-&#x3B2;-lactamase; CRKP, carbapenem-resistant <italic toggle="yes">Klebsiella pneumoniae</italic>; KPC-NDM-CRKP, KPC and NDM co-producing carbapenem-resistant <italic toggle="yes">Klebsiella pneumoniae</italic>; BSI, bloodstream infection; ICU, intensive care unit; PCT, procalcitonin; CRP, C-reactive protein; NEUT%, neutrophilic granulocyte percentage; APACHE, acute physiologic and chronic health evaluation; OR, odds ratio; CI, confidence interval.</p></fn></table-wrap-foot></table-wrap>
</p>
        <p>Multivariate analysis further demonstrated that ICU-acquired BSIs (95% CI 2.707&#x2013;38.559; <italic toggle="yes">P</italic> = 0.001), APACHE II score at BSI onset (95% CI 1.288&#x2013;1.599; <italic toggle="yes">P</italic> &lt; 0.001), and BSIs caused by KPC-NDM-CRKP (95% CI 1.103&#x2013;63.270; <italic toggle="yes">P</italic> = 0.04) were independent predictors for 30-day mortality in patients with CRKP bacteremia. Patients with longer length of full hospital stay (95% CI 0.937&#x2013;0.999; <italic toggle="yes">P</italic> = 0.043) and ICU stay (95% CI 0.921&#x2013;0.996; <italic toggle="yes">P</italic> = 0.03) had a significantly lower risk of nonsurvival (<xref rid="t0005" ref-type="table">Table 5</xref>).</p>
      </sec>
    </sec>
    <sec id="s0004">
      <title>Discussion</title>
      <p>To our knowledge, this is the first systematic study on KPC-NDM-CRKP, which provides the most comprehensive understanding of KPC-NDM-CRKP BSIs, including risk factors, molecular characteristics, and clinical outcomes. In this study, the 30-day mortality ranged from 32.5% in patients with KPC-CRKP BSIs to 56% in those with KPC-NDM-CRKP BSIs. These findings have remarkable importance and novelty.</p>
      <p>CRKP represents a devastating threat to global public health and clinical settings.<xref rid="cit0018" ref-type="bibr">18&#x2013;20</xref> The prevalence of meropenem-resistant <italic toggle="yes">K. pneumoniae</italic> has increased rapidly in China, from 2.9% in 2005 to 24.2% in 2022, according to the China Antimicrobial Surveillance Network (CHINET, <underline><ext-link xlink:href="http://www.chinets.com/" ext-link-type="uri">http://www.chinets.com/</ext-link></underline>). According to an antimicrobial resistance surveillance study from the Swiss ICU, carbapenem-resistant Enterobacterales (CRE) have been steadily increasing from 1% to 5% between 2008 and 2019.<xref rid="cit0021" ref-type="bibr">21</xref> The most common mechanism underlying carbapenem resistance in CRKP is the production of carbapenemases, including class A carbapenemases (mainly KPC), class B metallo-&#x3B2;-lactamases (MBLs, mainly NDM), and some class D OXA-48-like carbapenemases (mainly OXA-181 and OXA-232).<xref rid="cit0022" ref-type="bibr">22</xref>,<xref rid="cit0023" ref-type="bibr">23</xref></p>
      <p>Several recent studies have reported CRKPs carrying multiple carbapenemase genes.<xref rid="cit0024" ref-type="bibr">24</xref> KPC and NDM belong to different carbapenemase classes. KPCs hydrolyze penicillins, cephalosporins, carbapenems, and monobactams. Newer &#x3B2;-lactamase inhibitors, such as avibactam, relebactam, and vaborbactam, have activity against most KPC-CRKP isolates. On the contrary, NDMs hydrolyze penicillins, cephalosporins, and carbapenems, but not monobactams. Neither ceftazidime-avibactam, meropenem-vaborbactam, nor imipenem-cilastatin-relebactam has activity against NDM-CRKP isolates.<xref rid="cit0006" ref-type="bibr">6</xref>,<xref rid="cit0025" ref-type="bibr">25</xref> Thus, the synergistic effect of KPC and NDM results in higher level of antimicrobial resistance and extremely limited treatment options, which may further lead to increased mortality rates.</p>
      <p>Until 2020, the prevalence of KPC-NDM-CRKP strains was significantly lower than that of KPC-CRKP or NDM-CRKP. The Chinese Carbapenem-resistant Enterobacteriaceae (CRE) Network detected a total of seven strains of KPC-2-NDM-1-CRKP (0.34%) within a collection of 2057 CRKP isolated from 2012 to 2017 in China.<xref rid="cit0003" ref-type="bibr">3</xref> Only three KPC-NDM-CRKPs (0.06%) were identified out of 4635 <italic toggle="yes">K. pneumoniae</italic> species complex bloodstream isolates that were collected between 2014 and 2019, according to the Blood Bacterial Resistant Investigation Collaborative System (BRICS) in China.<xref rid="cit0026" ref-type="bibr">26</xref> In the United States, the Centers for Disease Control and Prevention (CDC) and the Antibiotic Resistance Laboratory Network (AR Lab Network) reported 12 cases of KPC-NDM-CRKP infections between 2012 and 2019.<xref rid="cit0024" ref-type="bibr">24</xref> An epidemiological study in the United States reported the trends of carbapenemases among CRE. A total of 27,834 Enterobacterales isolates were collected from 74 US medical centers consecutively between 2019 and 2021. Three <italic toggle="yes">K. pneumoniae</italic> isolates had two carbapenemases: one carrying <italic toggle="yes">bla</italic><sub>NDM-1</sub> and <italic toggle="yes">bla</italic><sub>OXA-181</sub>, and two isolates carrying <italic toggle="yes">bla</italic><sub>NDM-5</sub> and <italic toggle="yes">bla</italic><sub>OXA-181</sub>, with none of KPC-NDM-CRKP detected.<xref rid="cit0027" ref-type="bibr">27</xref> In a surveillance study conducted in Europe, a total of 310 carbapenem-resistant or intermediate <italic toggle="yes">K. pneumoniae</italic> isolates were collected in 15 Greek hospitals from 2013 to 2022. The presence of <italic toggle="yes">bla</italic><sub>KPC-2</sub> in different combinations with <italic toggle="yes">bla</italic><sub>NDM-1</sub>, <italic toggle="yes">bla</italic><sub>OXA-48</sub>, and/or <italic toggle="yes">bla</italic><sub>VIM-1</sub> was observed in 24 specimens.<xref rid="cit0028" ref-type="bibr">28</xref></p>
      <p>Unfortunately, sporadic cases of KPC-NDM-CRKP strains have been increasingly reported worldwide in recent years. In 2021, Huang et al reported that a KPC-2-producing <italic toggle="yes">K. pneumoniae</italic> strain acquired a <italic toggle="yes">bla</italic><sub>NDM-5</sub>-harbouring plasmid during ceftazidime/avibactam treatment.<xref rid="cit0029" ref-type="bibr">29</xref> The emergence of CRKP coharboring <italic toggle="yes">bla</italic><sub>KPC-3</sub> and <italic toggle="yes">bla</italic><sub>NDM-1</sub>,<xref rid="cit0030" ref-type="bibr">30</xref> CRKP coharboring <italic toggle="yes">bla</italic><sub>KPC-2</sub> and <italic toggle="yes">bla</italic><sub>NDM-6</sub>,<xref rid="cit0031" ref-type="bibr">31</xref> hypervirulent CRKP coharboring <italic toggle="yes">bla</italic><sub>KPC-2</sub> and <italic toggle="yes">bla</italic><sub>NDM-1</sub>,<xref rid="cit0032" ref-type="bibr">32</xref> tigecycline-resistant hypervirulent <italic toggle="yes">K. pneumoniae</italic> cocarrying <italic toggle="yes">bla</italic><sub>KPC-2</sub> and <italic toggle="yes">bla</italic><sub>NDM-5</sub>,<xref rid="cit0033" ref-type="bibr">33</xref> polymyxin B-resistant hypervirulent <italic toggle="yes">K. pneumoniae</italic> coharboring <italic toggle="yes">bla</italic><sub>KPC-2</sub> and <italic toggle="yes">bla</italic><sub>NDM-1</sub>,<xref rid="cit0034" ref-type="bibr">34</xref> and CRKP coharboring <italic toggle="yes">bla</italic><sub>KPC-2</sub>, <italic toggle="yes">bla</italic><sub>NDM-1</sub>, and <italic toggle="yes">tmexCD1-toprJ1</italic> have been successively reported.<xref rid="cit0035" ref-type="bibr">35</xref></p>
      <p>The proportion of KPC-NDM-CRKP isolates was 10.8%, which was 30 times higher than that reported in the previous study. Additionally, 20 isolates of ST11 KPC-2-NDM-5-CRKP, three isolates of ST11 KPC-2-NDM-1-CRKP, and two isolates of ST15 KPC-2-NDM-5-CRKP were identified in the present study. Combined, these data suggested that the nosocomial infection transmission might contribute to the extraordinary high prevalence and mortality of KPC-NDM-CRKPs. Therefore, infection prevention and control measures should be taken to prevent pathogen transmission and reduce the risk of death. The basic operations include the isolation management of infected patients, ensuring hand hygiene, periodic environmental cleansing, and equipment disinfection.</p>
      <p>KPC-NDM-CRKP has been increasingly reported but has not yet been systematically studied. Several studies have been conducted on risk factors for CRKP BSIs but have combined heterogeneous data with different carbapenemase types (including KPC, NDM, and OXA-48-like).<xref rid="cit0036" ref-type="bibr">36</xref> Previous studies have shown that both ICU-acquired, length of hospital stay and operation history increased the risk of CRKP infection compared with carbapenem-susceptible <italic toggle="yes">K. pneumoniae</italic> (CSKP),<xref rid="cit0009" ref-type="bibr">9</xref>,<xref rid="cit0037" ref-type="bibr">37</xref> while our study found that these also increased the risk of KPC-NDM-CRKP infection compared with KPC-CRKP. Multicenter prospective studies with larger samples should be performed to identify more risk factors for KPC-NDM-CRKP infection.</p>
      <p>In addition, there was little information on infection data for BSIs caused by KPC-NDM-CRKPs. The levels of inflammation markers, including WBC count, NEUT%, PCT, CRP, albumin, and platelet count, exhibited no significant differences between the two groups. The patients who suffered KPC-NDM-CRKP BSIs appeared significantly higher in the Pitt bacteremia score at infection onset (<italic toggle="yes">P</italic> = 0.023). However, no statistically significant differences were observed in the APACHE II score (<italic toggle="yes">P</italic> = 0.192) or the occurrence of sepsis or septic shock at the onset of BSIs (<italic toggle="yes">P</italic> = 0.218) in both groups.</p>
      <p>Several studies have also described an increased mortality of CRKP BSIs compared with CSKP BSIs. According to a meta-analysis of 37 papers published between 2009 and 2017, the overall mortality rate associated with KPC-CRKP infection was 41.0%, with oncology patients having the highest mortality rate at 56.0%.<xref rid="cit0038" ref-type="bibr">38</xref> A prospective cohort study in 19 Italian hospitals estimated the mortality attributable to different types of carbapenem-resistant gram-negative bacilli (GNB). The 30-day mortality rates were 26.6% and 36.4% in patients with BSIs caused by KPC-producing CRE and MBL-producing CRE, respectively.<xref rid="cit0010" ref-type="bibr">10</xref> However, currently, no research has been conducted to explicitly investigate the clinical outcomes of BSIs induced by KPC-NDM-CRKP. In the present study, BSIs caused by KPC-NDM-CRKP showed significantly higher 30-day mortality compared to KPC-CRKP BSIs (56%, 14/25 vs 32.5%, 67/206, <italic toggle="yes">P</italic> = 0.02). This observation is particularly significant given the changing epidemiology of CRKP on a global scale. At the outset of the study design, both KPC-CRKP and NDM-CRKP BSIs were assigned as control groups to investigate the synergistic effect of KPC and NDM in CRKPs. However, only four isolates carrying <italic toggle="yes">bla</italic><sub>NDM</sub> were detected using PCR and WGS during the three years, and one of four (25%) patients did not survive. Due to the limited sample size, the four patients with NDM-CRKP BSIs were excluded from this study.</p>
      <p>Appropriate empirical therapy was associated with decreased risk of mortality in patients with CRKP BSIs.<xref rid="cit0039" ref-type="bibr">39</xref> However, receiving appropriate empirical antibiotics did not show a protective effect on the prognosis of patients who had CRKP BSIs in our study. During the study period, tigecycline-containing regimens (n = 75, 32.5%) and colistin-containing regimens (n = 56, 24.2%) were the major antibiotics administered for empirical treatment. Among 231 CRKP isolates, 35.1% (81/231) were resistant to tigecycline, and 10% (23/231) were resistant to colistin. Colistin and tigecycline had a lower resistance rate to CRKP isolates in our investigation.</p>
      <p>Based on previous studies, the effectiveness of using tigecycline was comparable to other antimicrobial drugs in treating BSIs caused by CRKP with a MIC of 0.5 mg/L or below.<xref rid="cit0040" ref-type="bibr">40</xref> Nevertheless, only four isolates (1.7%) showed MICs of tigecycline &#x2264; 0.5 mg/L in our study. Moreover, tigecycline is not suggested for the treatment of CRE BSIs.<xref rid="cit0005" ref-type="bibr">5</xref> Although colistin is the main available and in vitro susceptible antibiotic, several observational studies and randomized controlled trials have demonstrated that treatment with colistin in CRKP BSI patients is associated with higher mortality and increased nephrotoxicity relative to comparator agents.<xref rid="cit0041" ref-type="bibr">41</xref>,<xref rid="cit0042" ref-type="bibr">42</xref> Colistin is not recommended for treating infections caused by CRE.<xref rid="cit0005" ref-type="bibr">5</xref> All six patients in our study who had KPC-NDM-CRKP BSIs and were treated with colistin as initial therapy unfortunately did not survive. Not surprisingly, colistin-containing empirical treatment was a risk factor for 30-day mortality of CRKP BSI in univariate analysis (95% CI 1.244&#x2013;4.258; <italic toggle="yes">P</italic> = 0.008). Additionally, a total of six patients (24%, 6/25) with KPC-NDM-CRKP BSIs received ceftazidime/avibactam as empirical therapy and four of these patients died. Therefore, the ability to detect and differentiate carbapenemases rapidly might be considered crucial for initial antibiotic therapy.<xref rid="cit0043" ref-type="bibr">43</xref></p>
      <p>Regarding the treatment of patients with KPC-NDM-CRKP, the preferable options can refer to the Infectious Diseases Society of America (IDSA) guidelines on MBL-producing CRE, which recommend a combination regimen of ceftazidime-avibactam and aztreonam or monotherapy of cefiderocol.<xref rid="cit0005" ref-type="bibr">5</xref> A recent meta-analysis including four articles with a moderate or serious risk of bias found that the combination of ceftazidime-avibactam and aztreonam was associated with lower 30-day mortality when compared to polymyxins in patients with MBL-producing CRE BSI.<xref rid="cit0044" ref-type="bibr">44</xref> Cefiderocol has a strong stability of carbapenemases. Two clinical trials including patients with MBL-producing infections showed that the clinical cure of cefiderocol was higher than that of alternate therapy (70.8% vs 40%).<xref rid="cit0045" ref-type="bibr">45</xref></p>
      <p>The main limitation of our study derives from its retrospective design and a relatively small study population. Given that it was a retrospective study, exposure history to antimicrobial agents, previous history of CRKP infection within 90 days prior to BSI, and CRKP colonization could not be obtained due to a lack of sufficient data. The relevant analysis for KPC-NDM-CRKP and KPC-CRKP subgroups was not implemented because of the limited sample size. Future studies could further investigate the risk factors and attributable mortality of patients with BSIs caused by KPC-NDM-CRKP after taking these factors into account.</p>
    </sec>
    <sec id="s0005">
      <title>Conclusion</title>
      <p>In conclusion, our study included 231 patients, not a large number, but to date, it is the first and largest cohort to investigate the risk factors and outcomes of KPC-NDM-CRKP BSIs compared with KPC-CRKP BSIs, to our knowledge. Our data indicated that KPC-NDM-CRKP strains were strongly associated with clinical mortality in cases of BSIs. This finding highlights the need for increased attention, as the prevalence of KPC-NDM-CRKPs is growing globally.</p>
    </sec>
  </body>
  <back>
    <sec id="s0006">
      <title>Ethics Approval and Informed Consent</title>
      <p>This retrospective study was conducted in accordance with the ethical standards of the Institutional Review Board Ethics Committee of Jinling Hospital (2022DZSKT-007) and the Declaration of Helsinki and national and institutional standards. The requirement to obtain informed written consent was waived because the biometric information and data in this study have been de-identified, and any information obtained during the investigation will be treated with the utmost confidentiality.</p>
    </sec>
    <sec sec-type="COI-statement" id="s0007">
      <title>Disclosure</title>
      <p>The authors report no conflicts of interest in this work.</p>
    </sec>
    <ref-list>
      <title>References</title>
      <ref id="cit0001">
        <label>1.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Wang</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Earley</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>L</given-names></string-name>, et al. <article-title>Clinical outcomes and bacterial characteristics of carbapenem-resistant <italic toggle="yes">Klebsiella pneumoniae</italic> complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study</article-title>. <source><italic toggle="yes">Lancet Infect Dis</italic></source>. <year>2022</year>;<volume>22</volume>(<issue>3</issue>):<fpage>401</fpage>&#x2013;<lpage>412</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1473-3099(21)00399-6</pub-id><pub-id pub-id-type="pmid">34767753</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0002">
        <label>2.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Wu</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Wu</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Bao</surname>
<given-names>D</given-names></string-name>, et al. <article-title>Global evolution and geographic diversity of hypervirulent carbapenem-resistant <italic toggle="yes">Klebsiella pneumoniae</italic></article-title>. <source><italic toggle="yes">Lancet Infect Dis</italic></source>. <year>2022</year>;<volume>22</volume>(<issue>6</issue>):<fpage>761</fpage>&#x2013;<lpage>762</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1473-3099(22)00275-4</pub-id><pub-id pub-id-type="pmid">35643096</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0003">
        <label>3.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Gao</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>Q</given-names></string-name>, <string-name><surname>Jin</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>H</given-names></string-name>. <article-title>The transferability and evolution of NDM-1 and KPC-2 co-producing <italic toggle="yes">Klebsiella pneumoniae</italic> from clinical settings</article-title>. <source><italic toggle="yes">EBioMedicine</italic></source>. <year>2020</year>;<volume>51</volume>:<fpage>102599</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ebiom.2019.102599</pub-id><pub-id pub-id-type="pmid">31911273</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0004">
        <label>4.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Rong</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Yang</surname>
<given-names>P</given-names></string-name>, et al. <article-title>Epidemiological and Molecular Characteristics of bla (NDM-1) and bla (KPC-2) Co-Occurrence Carbapenem-Resistant <italic toggle="yes">Klebsiella pneumoniae</italic></article-title>. <source><italic toggle="yes">Infect Drug Resist</italic></source>. <year>2023</year>;<volume>16</volume>:<fpage>2247</fpage>&#x2013;<lpage>2258</lpage>. doi:<pub-id pub-id-type="doi">10.2147/IDR.S400138</pub-id><pub-id pub-id-type="pmid">37090038</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0005">
        <label>5.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Tamma</surname>
<given-names>PD</given-names></string-name>, <string-name><surname>Aitken</surname>
<given-names>SL</given-names></string-name>, <string-name><surname>Bonomo</surname>
<given-names>RA</given-names></string-name>, <string-name><surname>Mathers</surname>
<given-names>AJ</given-names></string-name>, <string-name><surname>van Duin</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Clancy</surname>
<given-names>CJ</given-names></string-name>. <article-title>Infectious diseases society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections</article-title>. <source><italic toggle="yes">Clin Infect Dis</italic></source>. <year>2023</year>. doi:<pub-id pub-id-type="doi">10.1093/cid/ciad428</pub-id></mixed-citation>
      </ref>
      <ref id="cit0006">
        <label>6.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Wu</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Feng</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Tang</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Qiao</surname>
<given-names>F</given-names></string-name>, <string-name><surname>McNally</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Zong</surname>
<given-names>Z</given-names></string-name>. <article-title>NDM Metallo-&#x3B2;-Lactamases and their bacterial producers in health care settings</article-title>. <source><italic toggle="yes">Clin Microbiol Rev</italic></source>. <year>2019</year>;<volume>32</volume>(<issue>2</issue>):<fpage>e00115</fpage>&#x2013;<lpage>00118</lpage>. doi:<pub-id pub-id-type="doi">10.1128/CMR.00115-18</pub-id><pub-id pub-id-type="pmid">30700432</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0007">
        <label>7.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Jiang</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Huang</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Ding</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Ruan</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Yan</surname>
<given-names>J</given-names></string-name>. <article-title>Genomic and phylogenetic analysis of a multidrug-resistant bla(NDM)-carrying <italic toggle="yes">Klebsiella michiganensis</italic> in China</article-title>. <source><italic toggle="yes">Infect Drug Resist</italic></source>. <year>2023</year>;<volume>16</volume>:<fpage>3109</fpage>&#x2013;<lpage>3116</lpage>. doi:<pub-id pub-id-type="doi">10.2147/IDR.S409544</pub-id><pub-id pub-id-type="pmid">37228660</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0008">
        <label>8.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Mojica</surname>
<given-names>MF</given-names></string-name>, <string-name><surname>Rossi</surname>
<given-names>MA</given-names></string-name>, <string-name><surname>Vila</surname>
<given-names>AJ</given-names></string-name>, <string-name><surname>Bonomo</surname>
<given-names>RA</given-names></string-name>. <article-title>The urgent need for metallo-beta-lactamase inhibitors: an unattended global threat</article-title>. <source><italic toggle="yes">Lancet Infect Dis</italic></source>. <year>2022</year>;<volume>22</volume>(<issue>1</issue>):<fpage>e28</fpage>&#x2013;<lpage>e34</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1473-3099(20)30868-9</pub-id><pub-id pub-id-type="pmid">34246322</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0009">
        <label>9.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Lou</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Du</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>P</given-names></string-name>, et al. <article-title>Risk factors for infection and mortality caused by carbapenem-resistant <italic toggle="yes">Klebsiella pneumoniae</italic>: a large multicentre case-control and cohort study</article-title>. <source><italic toggle="yes">J Infect</italic></source>. <year>2022</year>;<volume>84</volume>(<issue>5</issue>):<fpage>637</fpage>&#x2013;<lpage>647</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jinf.2022.03.010</pub-id><pub-id pub-id-type="pmid">35301013</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0010">
        <label>10.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Falcone</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Tiseo</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Carbonara</surname>
<given-names>S</given-names></string-name>, et al. <article-title>Mortality attributable to bloodstream infections caused by different carbapenem-resistant gram-negative bacilli: results from a nationwide study in Italy (ALARICO Network)</article-title>. <source><italic toggle="yes">Clin Infect Dis</italic></source>. <year>2023</year>;<volume>76</volume>(<issue>12</issue>):<fpage>2059</fpage>&#x2013;<lpage>2069</lpage>. doi:<pub-id pub-id-type="doi">10.1093/cid/ciad100</pub-id><pub-id pub-id-type="pmid">36801828</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0011">
        <label>11.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Li</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Ren</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>W</given-names></string-name>, et al. <article-title>Risk factors and clinical outcomes of hypervirulent <italic toggle="yes">Klebsiella pneumoniae</italic> induced bloodstream infections</article-title>. <source><italic toggle="yes">Eur J Clin Microbiol Infect Dis</italic></source>. <year>2018</year>;<volume>37</volume>(<issue>4</issue>):<fpage>679</fpage>&#x2013;<lpage>689</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10096-017-3160-z</pub-id><pub-id pub-id-type="pmid">29238932</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0012">
        <label>12.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Singer</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Deutschman</surname>
<given-names>CS</given-names></string-name>, <string-name><surname>Seymour</surname>
<given-names>CW</given-names></string-name>, et al. <article-title>The third international consensus definitions for sepsis and septic shock (Sepsis-3)</article-title>. <source><italic toggle="yes">JAMA</italic></source>. <year>2016</year>;<volume>315</volume>(<issue>8</issue>):<fpage>801</fpage>&#x2013;<lpage>810</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2016.0287</pub-id><pub-id pub-id-type="pmid">26903338</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0013">
        <label>13.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Jenkins</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Ledeboer</surname>
<given-names>NA</given-names></string-name>, <string-name><surname>Westblade</surname>
<given-names>LF</given-names></string-name>, et al. <article-title>Evaluation of NG-Test Carba 5 for rapid phenotypic detection and differentiation of five common carbapenemase families: results of a multicenter clinical evaluation</article-title>. <source><italic toggle="yes">J Clin Microbiol</italic></source>. <year>2020</year>;<volume>58</volume>(<issue>7</issue>):<fpage>e00344</fpage>&#x2013;<lpage>00320</lpage>. doi:<pub-id pub-id-type="doi">10.1128/JCM.00344-20</pub-id><pub-id pub-id-type="pmid">32376668</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0014">
        <label>14.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Han</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Guo</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Peng</surname>
<given-names>M</given-names></string-name>, et al. <article-title>Evaluation of the Immunochromatographic NG-Test Carba 5, RESIST-5 O.O.K.N.V. and IMP K-SeT for Rapid Detection of KPC-, NDM-, IMP-, VIM-type, and OXA-48-like Carbapenemase Among Enterobacterales</article-title>. <source><italic toggle="yes">Front Microbiol</italic></source>. <year>2020</year>;<volume>11</volume>:<fpage>609856</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fmicb.2020.609856</pub-id><pub-id pub-id-type="pmid">33519761</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0015">
        <label>15.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Lam</surname>
<given-names>MMC</given-names></string-name>, <string-name><surname>Wick</surname>
<given-names>RR</given-names></string-name>, <string-name><surname>Watts</surname>
<given-names>SC</given-names></string-name>, <string-name><surname>Cerdeira</surname>
<given-names>LT</given-names></string-name>, <string-name><surname>Wyres</surname>
<given-names>KL</given-names></string-name>, <string-name><surname>Holt</surname>
<given-names>KE</given-names></string-name>. <article-title>A genomic surveillance framework and genotyping tool for <italic toggle="yes">Klebsiella pneumoniae</italic> and its related species complex</article-title>. <source><italic toggle="yes">Nat Commun</italic></source>. <year>2021</year>;<volume>12</volume>(<issue>1</issue>):<fpage>4188</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41467-021-24448-3</pub-id><pub-id pub-id-type="pmid">34234121</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0016">
        <label>16.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Bortolaia</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Kaas</surname>
<given-names>RS</given-names></string-name>, <string-name><surname>Ruppe</surname>
<given-names>E</given-names></string-name>, et al. <article-title>ResFinder 4.0 for predictions of phenotypes from genotypes</article-title>. <source><italic toggle="yes">J Antimicrob Chemother</italic></source>. <year>2020</year>;<volume>75</volume>(<issue>12</issue>):<fpage>3491</fpage>&#x2013;<lpage>3500</lpage>. doi:<pub-id pub-id-type="doi">10.1093/jac/dkaa345</pub-id><pub-id pub-id-type="pmid">32780112</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0017">
        <label>17.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Alcock</surname>
<given-names>BP</given-names></string-name>, <string-name><surname>Raphenya</surname>
<given-names>AR</given-names></string-name>, <string-name><surname>Lau</surname>
<given-names>TTY</given-names></string-name>, et al. <article-title>CARD 2020: antibiotic resistome surveillance with the comprehensive antibiotic resistance database</article-title>. <source><italic toggle="yes">Nucleic Acids Res</italic></source>. <year>2020</year>;<volume>48</volume>(<issue>D1</issue>):<fpage>D517</fpage>&#x2013;<lpage>D525</lpage>. doi:<pub-id pub-id-type="doi">10.1093/nar/gkz935</pub-id><pub-id pub-id-type="pmid">31665441</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0018">
        <label>18.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Chi</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Meng</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Xiong</surname>
<given-names>L</given-names></string-name>, et al. <article-title>Small wards in the ICU: a favorable measure for controlling the transmission of carbapenem-resistant <italic toggle="yes">Klebsiella pneumoniae</italic></article-title>. <source><italic toggle="yes">Intensive Care Med</italic></source>. <year>2022</year>;<volume>48</volume>(<issue>11</issue>):<fpage>1573</fpage>&#x2013;<lpage>1581</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00134-022-06881-0</pub-id><pub-id pub-id-type="pmid">36129475</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0019">
        <label>19.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Wang</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Zhan</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>J</given-names></string-name>, et al. <article-title>Prevalence of Carbapenem-Resistant <italic toggle="yes">Klebsiella pneumoniae</italic> Infection in a Northern Province in China: Clinical characteristics, drug resistance, and geographic distribution</article-title>. <source><italic toggle="yes">Infect Drug Resist</italic></source>. <year>2022</year>;<volume>15</volume>:<fpage>569</fpage>&#x2013;<lpage>579</lpage>. doi:<pub-id pub-id-type="doi">10.2147/IDR.S347343</pub-id><pub-id pub-id-type="pmid">35228807</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0020">
        <label>20.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Wu</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Jiang</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Zhou</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Kuang</surname>
<given-names>L</given-names></string-name>. <article-title>Genomic characteristics of Carbapenem-Resistant <italic toggle="yes">Klebsiella pneumoniae</italic> isolated from neonatal patients in Southwest China during 2017&#x2013;2021</article-title>. <source><italic toggle="yes">Infect Drug Resist</italic></source>. <year>2023</year>;<volume>16</volume>:<fpage>6725</fpage>&#x2013;<lpage>6733</lpage>. doi:<pub-id pub-id-type="doi">10.2147/IDR.S426565</pub-id><pub-id pub-id-type="pmid">37868700</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0021">
        <label>21.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Barnsteiner</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Baty</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Albrich</surname>
<given-names>WC</given-names></string-name>, et al. <article-title>Antimicrobial resistance and antibiotic consumption in intensive care units, Switzerland, 2009 to 2018</article-title>. <source><italic toggle="yes">Euro Surveill</italic></source>. <year>2021</year>;<volume>26</volume>(<issue>46</issue>):<fpage>2001537</fpage>. doi:<pub-id pub-id-type="doi">10.2807/1560-7917.ES.2021.26.46.2001537</pub-id><pub-id pub-id-type="pmid">34794535</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0022">
        <label>22.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Roach</surname>
<given-names>DJ</given-names></string-name>, <string-name><surname>Sridhar</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Oliver</surname>
<given-names>E</given-names></string-name>, et al. <article-title>Clinical and genomic characterization of a cohort of patients with <italic toggle="yes">Klebsiella pneumoniae</italic> bloodstream infection</article-title>. <source><italic toggle="yes">Clin Infect Dis</italic></source>. <year>2023</year>;<fpage>5379</fpage>&#x2014;<lpage>5385</lpage>.</mixed-citation>
      </ref>
      <ref id="cit0023">
        <label>23.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Wu</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Jiang</surname>
<given-names>T</given-names></string-name>, <string-name><surname>He</surname>
<given-names>X</given-names></string-name>, et al. <article-title>Global phylogeography and genomic epidemiology of Carbapenem-Resistant bla(OXA-232)-carrying <italic toggle="yes">Klebsiella pneumoniae</italic> sequence type 15 lineage</article-title>. <source><italic toggle="yes">Emerg Infect Dis</italic></source>. <year>2023</year>;<volume>29</volume>(<issue>11</issue>):<fpage>2246</fpage>&#x2013;<lpage>2256</lpage>. doi:<pub-id pub-id-type="doi">10.3201/eid2911.230463</pub-id><pub-id pub-id-type="pmid">37877525</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0024">
        <label>24.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Ham</surname>
<given-names>DC</given-names></string-name>, <string-name><surname>Mahon</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Bhaurla</surname>
<given-names>SK</given-names></string-name>, et al. <article-title>Gram-negative bacteria harboring multiple carbapenemase genes, United States, 2012&#x2013;2019</article-title>. <source><italic toggle="yes">Emerg Infect Dis</italic></source>. <year>2021</year>;<volume>27</volume>(<issue>9</issue>):<fpage>2475</fpage>&#x2013;<lpage>2479</lpage>. doi:<pub-id pub-id-type="doi">10.3201/eid2709.210456</pub-id><pub-id pub-id-type="pmid">34424168</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0025">
        <label>25.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Yang</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Yan</surname>
<given-names>YH</given-names></string-name>, <string-name><surname>Schofield</surname>
<given-names>CJ</given-names></string-name>, <string-name><surname>McNally</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Zong</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>GB</given-names></string-name>. <article-title>Metallo-&#x3B2;-lactamase-mediated antimicrobial resistance and progress in inhibitor discovery</article-title>. <source><italic toggle="yes">Trends Microbiol</italic></source>. <year>2023</year>;<volume>31</volume>(<issue>7</issue>):<fpage>735</fpage>&#x2013;<lpage>748</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.tim.2023.01.013</pub-id><pub-id pub-id-type="pmid">36858862</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0026">
        <label>26.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Zhou</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Xue</surname>
<given-names>CX</given-names></string-name>, <string-name><surname>Xu</surname>
<given-names>T</given-names></string-name>, et al. <article-title>A point mutation in recC associated with subclonal replacement of carbapenem-resistant <italic toggle="yes">Klebsiella pneumoniae</italic> ST11 in China</article-title>. <source><italic toggle="yes">Nat Commun</italic></source>. <year>2023</year>;<volume>14</volume>(<issue>1</issue>):<fpage>2464</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41467-023-38061-z</pub-id><pub-id pub-id-type="pmid">37117217</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0027">
        <label>27.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Sader</surname>
<given-names>HS</given-names></string-name>, <string-name><surname>Mendes</surname>
<given-names>RE</given-names></string-name>, <string-name><surname>Carvalhaes</surname>
<given-names>CG</given-names></string-name>, <string-name><surname>Kimbrough</surname>
<given-names>JH</given-names></string-name>, <string-name><surname>Castanheira</surname>
<given-names>M</given-names></string-name>. <article-title>Changing Epidemiology of carbapenemases among carbapenem-resistant enterobacterales from United States Hospitals and the Activity of Aztreonam-Avibactam Against contemporary Enterobacterales (2019&#x2013;2021)</article-title>. <source><italic toggle="yes">Open Forum Infect Dis</italic></source>. <year>2023</year>;<volume>10</volume>(<issue>2</issue>):<fpage>ofad046</fpage>. doi:<pub-id pub-id-type="doi">10.1093/ofid/ofad046</pub-id><pub-id pub-id-type="pmid">36846612</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0028">
        <label>28.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Tryfinopoulou</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Linkevicius</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Pappa</surname>
<given-names>O</given-names></string-name>, et al. <article-title>Emergence and persistent spread of carbapenemase-producing <italic toggle="yes">Klebsiella pneumoniae</italic> high-risk clones in Greek hospitals, 2013 to 2022</article-title>. <source><italic toggle="yes">Euro Surveill</italic></source>. <year>2023</year>;<volume>28</volume>(<issue>47</issue>):<fpage>2300571</fpage>. doi:<pub-id pub-id-type="doi">10.2807/1560-7917.ES.2023.28.47.2300571</pub-id><pub-id pub-id-type="pmid">37997662</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0029">
        <label>29.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Huang</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Zhao</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Cao</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>B</given-names></string-name>. <article-title>Acquisition of a stable and transferable blaNDM-5-positive plasmid with low fitness cost leading to Ceftazidime/Avibactam Resistance in KPC-2-Producing <italic toggle="yes">Klebsiella pneumoniae</italic> during treatment</article-title>. <source><italic toggle="yes">Front Cell Infect Microbiol</italic></source>. <year>2021</year>;<volume>11</volume>:<fpage>658070</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fcimb.2021.658070</pub-id><pub-id pub-id-type="pmid">34354959</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0030">
        <label>30.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Saavedra</surname>
<given-names>SY</given-names></string-name>, <string-name><surname>Bernal</surname>
<given-names>JF</given-names></string-name>, <string-name><surname>Montilla-Escudero</surname>
<given-names>E</given-names></string-name>, et al. <article-title>Complexity of genomic epidemiology of Carbapenem-Resistant <italic toggle="yes">Klebsiella pneumoniae</italic> Isolates in Colombia urges the reinforcement of whole genome sequencing-based surveillance programs</article-title>. <source><italic toggle="yes">Clin Infect Dis</italic></source>. <year>2021</year>;<volume>73</volume>(<issue>Suppl_4</issue>):<fpage>S290</fpage>&#x2013;<lpage>S299</lpage>. doi:<pub-id pub-id-type="doi">10.1093/cid/ciab777</pub-id><pub-id pub-id-type="pmid">34850835</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0031">
        <label>31.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Zhu</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Ju</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Zhou</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Zhuge</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Dai</surname>
<given-names>J</given-names></string-name>. <article-title>Epidemiological characteristics of <italic toggle="yes">SHV, cmlv</italic>, and <italic toggle="yes">FosA6</italic>-producing carbapenem-resistant <italic toggle="yes">Klebsiella pneumoniae</italic> based on whole genome sequences in Jiangsu, China</article-title>. <source><italic toggle="yes">Front Microbiol</italic></source>. <year>2023</year>;<volume>14</volume>:<fpage>1219733</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fmicb.2023.1219733</pub-id><pub-id pub-id-type="pmid">37538843</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0032">
        <label>32.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Liu</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Long</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Xiang</surname>
<given-names>TX</given-names></string-name>, et al. <article-title>Whole genome assembly and functional portrait of hypervirulent extensively drug-resistant NDM-1 and KPC-2 co-producing <italic toggle="yes">Klebsiella pneumoniae</italic> of capsular serotype K2 and ST86</article-title>. <source><italic toggle="yes">J Antimicrob Chemother</italic></source>. <year>2019</year>;<volume>74</volume>(<issue>5</issue>):<fpage>1233</fpage>&#x2013;<lpage>1240</lpage>. doi:<pub-id pub-id-type="doi">10.1093/jac/dkz023</pub-id><pub-id pub-id-type="pmid">30843067</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0033">
        <label>33.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Huang</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Yi</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Yuan</surname>
<given-names>Y</given-names></string-name>, et al. <article-title>Emergence of a Fatal ST11-KL64 Tigecycline-Resistant Hypervirulent <italic toggle="yes">Klebsiella pneumoniae</italic> Clone Cocarrying blaNDM and blaKPC in Plasmids</article-title>. <source><italic toggle="yes">Microbiol Spectr</italic></source>. <year>2022</year>;<volume>10</volume>(<issue>6</issue>):<fpage>e0253922</fpage>. doi:<pub-id pub-id-type="doi">10.1128/spectrum.02539-22</pub-id><pub-id pub-id-type="pmid">36205391</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0034">
        <label>34.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Tang</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>Z</given-names></string-name>, et al. <article-title>Clonal transmission of polymyxin B-resistant hypervirulent <italic toggle="yes">Klebsiella pneumoniae</italic> isolates coharboring blaNDM-1 and blaKPC-2 in a tertiary hospital in China</article-title>. <source><italic toggle="yes">BMC Microbiol</italic></source>. <year>2023</year>;<volume>23</volume>(<issue>1</issue>):<fpage>64</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12866-023-02808-x</pub-id><pub-id pub-id-type="pmid">36882683</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0035">
        <label>35.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Liu</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Du</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Yang</surname>
<given-names>P</given-names></string-name>, et al. <article-title>Emergence and inter- and intrahost evolution of pandrug-resistant <italic toggle="yes">Klebsiella pneumoniae</italic> Coharboring <italic toggle="yes">tmexCD1-toprJ1</italic>, blaNDM-1, and blaKPC-2</article-title>. <source><italic toggle="yes">Microbiol Spectr</italic></source>. <year>2023</year>;<volume>11</volume>(<issue>2</issue>):<fpage>e02786</fpage>&#x2014;<lpage>22</lpage>.<pub-id pub-id-type="pmid">36719204</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0036">
        <label>36.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Wang</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Tian</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Zhao</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Gao</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Cui</surname>
<given-names>X</given-names></string-name>. <article-title>Analysis of risk factors for carbapenem resistant <italic toggle="yes">Klebsiella pneumoniae</italic> infection and construction of nomogram model: A large case-control and Cohort study from Shanxi, China</article-title>. <source><italic toggle="yes">Infect Drug Resist</italic></source>. <year>2023</year>;<volume>16</volume>:<fpage>7351</fpage>&#x2013;<lpage>7363</lpage>. doi:<pub-id pub-id-type="doi">10.2147/IDR.S442909</pub-id><pub-id pub-id-type="pmid">38050629</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0037">
        <label>37.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Huang</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Qiao</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Deng</surname>
<given-names>Y</given-names></string-name>, et al. <article-title>Analysis of risk factors associated with healthcare-associated carbapenem-resistant <italic toggle="yes">Klebsiella pneumoniae</italic> infection in a large general hospital: a case-case-control study</article-title>. <source><italic toggle="yes">Eur J Clin Microbiol Infect Dis</italic></source>. <year>2023</year>;<volume>42</volume>(<issue>5</issue>):<fpage>529</fpage>&#x2013;<lpage>541</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10096-023-04578-w</pub-id><pub-id pub-id-type="pmid">36856898</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0038">
        <label>38.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Ramos-Casta&#xF1;eda</surname>
<given-names>JA</given-names></string-name>, <string-name><surname>Ruano-Ravina</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Barbosa-Lorenzo</surname>
<given-names>R</given-names></string-name>, et al. <article-title>Mortality due to KPC carbapenemase-producing <italic toggle="yes">Klebsiella pneumoniae</italic> infections: Systematic review and meta-analysis: Mortality due to KPC <italic toggle="yes">Klebsiella pneumoniae</italic> infections</article-title>. <source><italic toggle="yes">J Infect</italic></source>. <year>2018</year>;<volume>76</volume>(<issue>5</issue>):<fpage>438</fpage>&#x2013;<lpage>448</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jinf.2018.02.007</pub-id><pub-id pub-id-type="pmid">29477802</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0039">
        <label>39.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Falcone</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Bassetti</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Tiseo</surname>
<given-names>G</given-names></string-name>, et al. <article-title>Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing <italic toggle="yes">Klebsiella pneumoniae</italic></article-title>. <source><italic toggle="yes">Crit Care</italic></source>. <year>2020</year>;<volume>24</volume>(<issue>1</issue>):<fpage>29</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13054-020-2742-9</pub-id><pub-id pub-id-type="pmid">32000834</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0040">
        <label>40.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Papadimitriou-Olivgeris</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Bartzavali</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Nikolopoulou</surname>
<given-names>A</given-names></string-name>, et al. <article-title>Impact of Tigecycline&#x2019;s MIC in the outcome of critically Ill Patients with Carbapenemase-Producing <italic toggle="yes">Klebsiella pneumoniae</italic> Bacteraemia Treated with Tigecycline Monotherapy-Validation of 2019&#x2019;s EUCAST Proposed Breakpoint Changes</article-title>. <source><italic toggle="yes">Antibiotics</italic></source>. <year>2020</year>;<volume>9</volume>(<issue>11</issue>):<fpage>828</fpage>. doi:<pub-id pub-id-type="doi">10.3390/antibiotics9110828</pub-id><pub-id pub-id-type="pmid">33228012</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0041">
        <label>41.</label>
        <mixed-citation publication-type="journal"><string-name><surname>van Duin</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Lok</surname>
<given-names>JJ</given-names></string-name>, <string-name><surname>Earley</surname>
<given-names>M</given-names></string-name>, et al. <article-title>Colistin Versus Ceftazidime-Avibactam in the treatment of infections due to Carbapenem-Resistant Enterobacteriaceae</article-title>. <source><italic toggle="yes">Clin Infect Dis</italic></source>. <year>2018</year>;<volume>66</volume>(<issue>2</issue>):<fpage>163</fpage>&#x2013;<lpage>171</lpage>. doi:<pub-id pub-id-type="doi">10.1093/cid/cix783</pub-id><pub-id pub-id-type="pmid">29020404</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0042">
        <label>42.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Motsch</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Murta de Oliveira</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Stus</surname>
<given-names>V</given-names></string-name>, et al. <article-title>RESTORE-IMI 1: a Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible bacterial infections</article-title>. <source><italic toggle="yes">Clin Infect Dis</italic></source>. <year>2020</year>;<volume>70</volume>(<issue>9</issue>):<fpage>1799</fpage>&#x2013;<lpage>1808</lpage>. doi:<pub-id pub-id-type="doi">10.1093/cid/ciz530</pub-id><pub-id pub-id-type="pmid">31400759</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0043">
        <label>43.</label>
        <mixed-citation publication-type="journal"><string-name><surname>La Villa S</surname>
<given-names>D</given-names></string-name>, <string-name><surname>S&#xE1;nchez-Carrillo</surname>
<given-names>C</given-names></string-name>, <string-name><surname>S&#xE1;nchez-Mart&#xED;nez</surname>
<given-names>C</given-names></string-name>, et al. <article-title>Clinical impact of time to results from the microbiology laboratory in bloodstream infections caused by carbapenemase-producing Enterobacterales (TIME-CPE STUDY)</article-title>. <source><italic toggle="yes">J Antimicrob Chemother</italic></source>. <year>2023</year>;<volume>78</volume>(<issue>8</issue>):<fpage>1948</fpage>&#x2013;<lpage>1954</lpage>. doi:<pub-id pub-id-type="doi">10.1093/jac/dkad188</pub-id><pub-id pub-id-type="pmid">37325878</pub-id>
</mixed-citation>
      </ref>
      <ref id="cit0044">
        <label>44.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Gupta</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Boodman</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Prayag</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Manesh</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Kumar</surname>
<given-names>TP</given-names></string-name>. <article-title>Ceftazidime-avibactam and aztreonam combination for Carbapenem-resistant Enterobacterales bloodstream infections with presumed Metallo-&#x3B2;-lactamase production: a systematic review and meta-analysis</article-title>. <source><italic toggle="yes">Expert Rev Anti Infect Ther</italic></source>. <year>2024</year>;<fpage>1</fpage>&#x2013;<lpage>7</lpage>.</mixed-citation>
      </ref>
      <ref id="cit0045">
        <label>45.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Timsit</surname>
<given-names>JF</given-names></string-name>, <string-name><surname>Paul</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Shields</surname>
<given-names>RK</given-names></string-name>, et al. <article-title>Cefiderocol for the treatment of infections due to Metallo-B-lactamase-Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 randomized studies</article-title>. <source><italic toggle="yes">Clin Infect Dis</italic></source>. <year>2022</year>;<volume>75</volume>(<issue>6</issue>):<fpage>1081</fpage>&#x2013;<lpage>1084</lpage>. doi:<pub-id pub-id-type="doi">10.1093/cid/ciac078</pub-id><pub-id pub-id-type="pmid">35148378</pub-id>
</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>